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Structure of the Dissertaion and Collaborators 
I have chosen a non-traditional format for this disseration in which published 
papers and preliminary publishable manuscripts together contain relevant background 
information and form the text of the document. Chapters 2, 3, and 4 are free standing 
manuscripts with their own introductions, thus they contain some repetition of the 
information in the introduction.  
Chapter 1, the introduction, provides a briefy overview of the Texaphyrin (MGd) 
synthesis and its conjugates. Additional information is available in the publication 
“Texaphyrin Conjugates. Progress Towards Second Generation Diagnostic and 
Therpaeutic Agents.” previously published in Macrocyclic Chemistry: Current Trends 
and Future Perspectives (2005), and the publication “Gadolinium texaphyrin-
methotrexate conjugates. Towards improved cancer chemotherapeutic agents,” published 
in Organic and Biomolecular Chemistry.1 2 The remainder of the introduction details 
published literature which must be credited with the intellectual foundation of this 
dissertation. This introductory information is largely regarding significant biological 
chemistry considerations in tumor biology, localization, imaging, and platinum 
chemistry.  
Chapter 2 consists of the manuscript entitled “Motexafin Gadolinium (MGd)-
Fluorophore Conjugates: Synthesis and Imaging in A549 Lung Cancer Cells.“ being 
prepared for submission to the Journal of Medicinal Chemistry.  
Chapter 3 consists of the manuscript entitled “Motexafin Gadolinium (MGd)-
Malonato-Platinum compounds: synthesis of new platinum conjugates and comparison 
vi 
with carboplatin in A549 lung cancer cells.“ also being prepared for submission to the 
Journal of Medicinal Chemistry.  
Chapter 4 consists of the manuscript entitled “Synthesis of [1-(phenylmethyl)-3,4-
diaminopyridinium chloride] dichloroplatinum and Activity in A549 Lung Cancer Cells.“ 
being prepared for submission to the Journal of Inorganic Biochemistry.  
All synthetic work was performed by the author. Dr. Hassan Naqui and Dr. 
Martin Poenie of the University of Texas Department of Cell Biology performed the 
MGd-fluorophore conjugate cell imaging and toxicity studies, as well as the biological 
testing of the Pt-quaternary compounds. Biological testing of the MGd-Pt conjugates was 
performed by Dr. Darren Magda at Pharmacyclics and Dr. Hassan Naqui and Dr. Martin 
Poenie of the University of Texas Department of Cell Biology. The candidate was 
responsible for producing initial and intermediate drafts.  It is important to stress the fact 
that Dr. Jonathan Sessler and Dr. Martin Poenie were responsible for polishing all final 
drafts of manuscripts, as well as this dissertation. Without their help in the writing 
process and logical flow, the clarity of  points significant to a wider audience would have 
suffered greatly. Credit goes to all the people contributing so much of their time and help 
in the completing of this work. Errors and omissions, of course, remain the responsibility 
of the author. 
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The experimental cancer therapeutic agent gadolinium texaphyrin (MGd) is a 
cationic paramagnetic expanded porphyrin currently being tested as an X-Ray sensitizing 
(XRS) agent, and is a compound with demonstrated tumor localization. Additionally 
MGd shows promise as a chemotherapeutic agent, both as a stand-alone agent, and  
showing activity in vitro with ascorbate via a novel ROS generating mechanism.3  This 
dissertation reports the synthesis, characterization, and cell studies of novel MGd-
fluorophore, and platinum therapeutic conjugates. Also discussed are cationic Pt agents 
having cytotoxic activity. 
In this research we set out to answer three questions:  i) can fluorescent 
conjugates of MGd be synthesized, with observable subcellular localization, different 
from that of MGd, ii) can MGd-Pt conjugates with observable Pt release be synthesized?, 
viii 
and iii) can Pt compounds containing a cationic moiety be tuned to have efficacy 
comparable to traditional Pt therapeutic agents?  
Two MGd-xanthene fluorophore conjugates were synthesized with the goal of 
using them to probe sub-cellular distribution. The anionic (FITC), and cationic 
(Rhodamine), fluorophore conjugates demonstrated nuclear and mitochondrial 
localization, respectively.  
In an ongoing project designed to reduce non-specific agent toxicity, a platinum-
releasing MGd therapeutic conjugate was synthesized. The MGd-amidopropylmalonato-
Pt conjugate demonstrated efficacy equivalent to carboplatin, a classical “non-selective” 
agent as inferred from in-vitro studies with A549 lung cancer cells. Aqueous stability 
studies of this conjugate gave results in agreement with hydrolytic loss of Pt, reversible 
with added Pt-diaquo. 
Finally, Pt complexes of amino-1-benzylpyridinium salts were synthesized and 
found to demonstrate significant cytotoxicity in screening studies. This latter positive 
development led to the suggestion that complexes of this type could consititute a new 
class of lipophilic-quaternary-cation Pt therapeutic agents. It is hoped that this series of 
putative Pt anti-cancer agents will prove useful as both stand-alone therapeutic agents and 
as the basis for producing conjugate with biolocalizing properties. 
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Nomenclature 
ACN – acetonitrile 
BOC – t-butyl carbamate 
FITC – Fluorescein isothiocyanate 
Futile Redox Cycling – A catalytic oxidation-reduction cycle within cells, generating 
toxic reactive oxygen species. Also called redox cycling 
M – Motexafin, the parent water solubilized texaphyrin ring.  The coordinated metal 
cation is given as a suffix, e.g. MGd, MLu, etc. 
MGd – Motexafin gadolinium, gadolinium texaphyrin 
PDT – Photodynamic therapy 
Rho – Rhodamine 
ROS – Reactive oxygen species (i.e. OH.  ,O2.  H2O2 ) 
Trans Effect – Activation for substitution on Pt of the position trans to a ligand; halides 
especially activate the trans position for substitution  
Tumor - An abnormal benign or malignant mass of tissue that is not inflammatory, arises 
without obvious cause from cells of preexistent tissue, and possesses no beneficial 
physiological function4 
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Chapter 1:  Introduction  
1.1 TEXAPHYRINS, CANCER AND PORPHYRINS  
In the 1980s Sessler and co-workers first synthesized the expanded-porphyrin 
“texaphyrin” ring system (Figure 1.1), 1.1 (abbreviated “M” – motexafin).5 Initially 
characterized in the solid state as the HSCN salt 1.1, the “sp3” form, a 24-electron non-
aromatic macrocycle, texaphyrin was later metallated and oxidized to the aromatic 22-
electron pentadentate Cd metallated planar “sp2”complex 1.2.6 Much later the unstable 
metal-free aromatic “sp2” form 1.3 was also prepared.7,8  The aromatic form proved to be 
a planar aromatic macrocycle. As such, this expanded structure with five fixed nitrogen 
atoms was considered likely to stabilize complexes with the larger lanthanide cations, 
including paramagnetic gadolinium(III) (MGd) 1.4.9 These expectations were, in fact, 
realized. 
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Figure 1.1.  Gadolinium Texaphyrin MGd Analogs 
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Due to the therapeutic potential of MGd as a Magentic Resonance Imaging (MRI) 
diagnostic agent and X-ray sensitizer (XRS), the original organic soluble peripherially-
alkylated texaphyrin structure was modified  to provide the water-soluble MGd analog 
1.4.10 Shown retrosynthetically (Scheme 1.1), the “sp3” texaphyrin ring can be considered 
as consisting of a tripyrrane fragment 1.5 and an o-phenylenediamine fragment 1.6 - 1.8. 
The tripyrrane fragment, 1.5a was modified to 1.5b, containing two pendant 
hydroxypropyl groups. Subsequently, the o-phenylene diamine moieties were 
functionalized, ultimately to the bis-PEG3OMe 1.6. The oxygenated o-phenylene diamine 
1.6 in turn was prepared from the stable dinitroveratrole-type compound 1.7 accessed 
specifically by nitration of veratrole 1.8. Thus, the synthesis of MGd, consists of catalytic 
reduction of the dinitro compound 1.7 to the unstable diamine compound 1.6 (prone to 
oxidation). This was then followed immediately by cyclization with tripyrrane 1.5b; this 
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Scheme 1.1.  Retrosynthesis showing water solubilizing modifications to MGd. 
3 
gave the sp3 texaphyrin 1.1(b). Metallation produced the water soluble MGd 1.4, a 
compound currently in clinical testing. These functionalized MGd products also 
demonstrated improved Gd-complex stability as compared to their non-oxygenated 
analogs prepared earlier. Presumably this reflects the more electron rich nature of the 
modified texaphyrin ring.11-13 Additional studies of MGd demonstrated useful redox 
chemistry, including generation of superoxide in the presence of ascorbate.14,15  On this 
basis, MGd was evaluated as a potential dual action MRI contrast agent and radiation 
sensitizer.16  
Preliminary animal and preclinical studies demonstrated tumor localization by 
MRI,  and efficacy over controls as an x-ray sensitizer.17-20 In clinical trials, the use of 
MGd as a radiation sensitizer gave rise to delays in the time to neurological progression 
of metastatic brain cancer, although not at the level of significance sufficient to warrant 
FDA approval.21  
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Figure 1.2  (A) Small tumor situated in tissue between blood vessel and lmphatic vessel. 
(B) Angiogenesis that increases the tumor’s blood supply, and lymph-angiogenesis, 
which has been correlated with disease severity and metastasis. 
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1.2 TUMOR BIOLOGY, CHEMOTHERAPY AND PORPHYRINOIDS  
 
The foundation of this work was the biological model of considering a tumor as 
an “organ” within the body. Thus targeting merely becomes a drug delivery exercise. 
Non-specific localization, giving undesired results, usually results in toxicity.  
While the tumor is considered a population of autonomous cells, growing as 
rapidly as possible, additionally significant, these cells are also genetically unstable.22 
The tumor’s genetic instability causes the constituent cells to become more 
heterogeneous and resistant to therapeutic treatment over time.23 Additionally, the central 
region of the tumor usually remaining hypoxic, contains both slowly growing cells, and 
cells undergoing necrosis (accidental cell death). These more slowly growing tumor cells 
typically have a higher resistance to chemotherapeutic agents. Thus, often a “cocktail,” 
consisting of a combination of several drugs, is given to overcome this treatment 
resistance.24  
The body’s blood circulation (Figure 1.2A) supplies a tumor with necessary 
oxygen and nutrients by diffusion from the blood vessels. With a normal blood supply, 
tumors typically become hypoxic on reaching 2-3 mm in diameter. A hypoxic tumor 
secreting hormones can stimulate new blood vessel development (angiogenesis).25 These 
new, immature and highly permeable blood vessels (Figure 1.2B) improve the oxygen 
and nutrient diffusion to the tumor. This results in the accumulation of macromolecules in 
the tumor by the so-called Enhanced Permeability and Retention (EPR) effect, where a 
tumor, lacking a lymphatic drainage system, retains macromolecules.26 The accumulated 
molecules include serum proteins and certain chemotherapeutic agents.27,28 This effect 
has been used therapeutically to target liposomes to tumors.29  While angiogenesis 
improves the tumor’s incoming blood/nutrient supply, not all tumors have an improved 
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drainage (lymphatic) system. Recent literature describes tumors that, again by hormone 
secretion, stimulate the development of a lymphatic drainage systems. The extent of so 
called  “lymph-angioigenesis” has been correlated with the disease severity (i.e. 
likelyhood of metastasis from the tumors).30 
Effective drugs minimally must reach their target tissues. Chemotherapeutic 
agents are typically administered intraveinously. Administration directly to the 
circulatory system maximizes drug bioavailability and avoids early drug metabolism 
occuring in the GI tract and liver (first pass effect). Often the administration of 
therapeutic agents having poor tumor localization is accompanied by systemic toxicity. 
This systemic toxicity can be caused by the metabolism of these drugs in non-target 
tissues. Theoretically, drugs with selective localization will display reduced systemic 
toxicity due to lower non-target tissue metabolism.  In accord with such thinking, 
chemotherapeutic agents that specifically localize in tumors have long been desired.  The 
question has thus focused on how to achieve this effect. Enhanced  localization at a target 
organ or site has been correlated with appropriate solubility, receptor binding, or rate of 
drug uptake within the target tissue.31-39 While drugs with these attributes may initially be 
distributed throughout the body, localization is often see subsequently through some 
combination of organ, structural, or cellular affinity. Therapeutic porphyrinoids, in 
analogy to biological porphyrinoids, represent a class of compounds that demonstrate 
accumulation in tumors. Additinally, porphyrinoids have been used synergistically in 
photodynamic therapy (PDT) demonstrating cytotoxic activity by the generation of 
reactive oxygen species (ROS).40 The texaphyrins are members of the “expanded 
porphyrin” class of macrocycles. These (larger) expanded porphyrins have demonstrated 
coordination of larger metals and allowed development of several additional experimental 
therapeutic agent that appear to be biologically well-tolerated.41 
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The porphyrinoids, (pyrrolic heterocycles containing four central nitrogen atoms),  
are widely distributed biologically, and are recognized for performing a variety of 
functions. These important redox-active molecules generally coordinate a core metal as in  
chlorophyll (Mg), cytochrome c (Fe), horseradish peroxidase (Fe), vitamin B-12 (Co), 
and heme (Fe). Taken in concert, these prosthetic groups help reduce CO2 to sugar, 
oxidize molecules, transport electrons, decompose peroxides, catalyze molecular 
rearrangements, and transport oxygen, respectively.42-47  
Porphyrinoid molecules 1.7 – 1.10, (Figure 1.3,) have been used in Photodynamic 
Therapy (PDT) applications, 1.7 (n = 1) since 1912. They were shown, as early as 1924, 
to localize selectively in tumors, and have been utilized in cancer PDT applications since 
the 1930s.48-50  Photofrin,® 1.7, Figure 1.3, is solubilized as the anionic polycarboxylate, 
was the first clinically approved porphyrinoid PDT agent.51,52 Photofrin,® a conceptual 
predecessor of MGd. is a complex mixture of porphyrin oligomers (active agent n = 2-3). 
It gained Canadian regulatory approval in 1993 after decades of clinical work starting in 
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Figure 1.3  Therapeutic PDT: Photofrin 1.7, Zn phthalocyanine 1.8,  
cationic porphyrin 1.9a, 1.9b, and MLu 1.10. 
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the 1960s. The drug demonstrated severe photo-toxicity, leading subsequently to the 
more purified form Photofrin II.® It also inspired the synthesis of additional agents, 
whose syntheses and use has been extensively reviewed in the literature.50,53-56 
The in vivo efficacy of Photofrin® 1.7 and its analogues has found to be 
correlated with lipophilicity and, to some extent, serum binding.53,57-62 These lipophilic 
porphyrinoids are generally thought to be bound to serum albumin during circulation.63  
Supporting the hypothesis of serum uptake by tumors is the activity demonstrated by low 
density lipoprotein (LDL), a serum component that has been utilized to develop 
therapeutic conjugates.64 Other serum binding effects have been observed in vivo, where 
non-toxic porphyrinoids displaced serum bound therapeutic porphyrinoids, resulting in 
higher efficacy.65,66   
An additional study with oligoporphyrins  - the higher molecular weight fraction 
of Photofrin® demonstrated higher tumor retention of the lipophilic oligomers (n = 4, 5, 
7, 8).67 Similarly, MGd 1.4, on reacting with oxalate forms a coordination polymer, 
which was found to have improved tumor uptake relative to the monomeric form.68 
One of the difficulties associated with developing porphyrinoid therapeutic agents 
is that some degree of water solubility is required for formulation along with a reasonable 
degree of lipophilicity to enhance activity as discussed above.69 Solubility, in several 
recent cases, has been effected through the use of the amphiphilic methoxy ethoxy group, 
polyethylene glycol, termed “PEG” for short (see Scheme 1.1, 1.8). This is due to many 
PEG functionalized porphyrinoids demonstrating both adequate water solubility and 
amphiphilic/lipophilic characteristics. It is believed that the non-toxic PEG embeds in 
membranes, as demonstrated from cell fusion studies, and assists in the cellular uptake of 
compounds that may otherwise lack toxic effects.70,71 The amphiphilic PEG group has 
been used extensively as a solubilizing agent for both chemotherapeutic agents (e.g. 
8 
doxorubicin, Pt-malonates), as well as therapeutic conjugates.72,73 This is particularly true 
in the porphyrinoid class, with examples including Hp-Pt and MGd-Pt conjugates.72-76  
 
1.3 CELLULAR UPTAKE AND LOCALIZATION OF MATERIALS 
 
The uptake of material into cells is typically mediated by the continual process of 
endocytosis (Figure 1.4A – 1.4D). Cellular uptake of porphyrinoids is generally attributed 
to this “absorptive endocytosis,” which has been referred to as a “fluid-phase” 
mechanism.77 In this process, cave-like structures are formed, mediated by the protein 
caveolin, and the exogenous agent is engulfed along with a portion of the surrounding 
fluid (Figure 1.4A). Uptake can be non-specific. However, in some cases exogenous 
species taken in are receptor bound. In both cases internal chambers, called endosomes, 
(Figure 1.4B) are formed. During endocytosis, the formed endosome is acidified, with the 
pH changing from 7.4 to 4.2, (Figure 1.4B - C). This results in the release of the receptor 
bound compounds from the cellular receptors (Figure 1.4C), which are recycled to the 
cell membrane (Figure 1.4D). The pH within the endosomes is thought to become 
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Figure 1.4  Endocytosis: A) Cave-like uptake structure, B) Vesicle acidification 
and substrate release, C) Receptor clustering, D) Receptor return to membrane 
leaving vesicle containing substrate molecules. 
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progressively lower on moving further into the cell, a process that has has been suggested 
as a sorting mechanism in sub-cellular trafficking.78 
As noted above, the internalized materials are initially contained in endosomes.79 
In normal cells, these endosomes process and distribute molecules to the cytoplasm or 
organelles. Alternatively the molecules can be re-excreted from the cell.80 Lipophilic, 
amphiphilic and positively charged molecules, generally pass rapidly out of the 
endosomes. 81,82  Macromolecules that are too large to pass through the lysosomal 
membrane demonstrate retention until digested. Anions compartmentalized within the 
endosome, repelled by the negative charge on membrane phospholipids, may be retainied 
in the endosomes until excreted from the cell.80   
As noted above, lipophilicity plays a significant role in the in vivo tumor 
localization of porphyrinoid therapeutic agents. While the localization and therapeutic 
activity of PDT agents 1.7-1.10, has been extensively studied at the sub-cellular level, 
there are relatively few examples attributing therapeutic activity to (extracellular) tumor 
vasculature damage.60,62,83-85 Due to the high reactivity of the reactive oxygen species 
(ROS) these agents produce, the damage to biomolecules they effect is localized. 
Nonetheless there is a general attempt is to develop ROS agents that stimulate the 
apoptosis pathway, resulting in “natural cell death.” The cellular uptake and movement of 
these ROS generating PDT agents has been imaged utilizing fluorescence microscopy. 
For instance porphycene dimer (PcD) 1.7 localizes at the cell membrane and in 
the lysosomes, and was found to be active therapeutically upon irradiation and to give 
rise to apoptosis.49 From imaging studies it was found that (anioinic) porphyrin PDT 
agents demonstrate sub-cellular redistribution during and after therapeutic incubation, 
which may correlate with efficacy.86  
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One specific example is provided from fluorescence-based imaging studies 
involving Zn phthalocynanines (ZnPcy). The localized, charged (+/-) ZnPcy species 
(Figure 1.3 1.8a, 1.8b) were observed to relocalize on irradiation. The least toxic, 
(hydrophilic) uncharged derivative (1.8c), which demonstrated Golgi localization, 
showed a slight cytoplasmic distribution on irradiation, in agreement with the above 
mentioned lipophilicity-toxicity correlation.87 In this case derivatives 1.8a, 1.8b, and 1.8c 
with peripherial positive, negative, and neutral substitution demonstrated efficacy, with 
ED50 values of 0.27, 3.02, and 34.4 uM, respectively, being observed.  
A number of cationic porphyrins have demonstrated specific sub-cellular 
localization, often mitochondrial, as well as DNA binding activity.88 Using the cationic 
porphyrinoid PDT agents 1.9a and 1.9b differing sub-cellular localization and efficacy 
patterns have been observed.89 Altering the position of the charge on the porphyrin ring 
periphery from 1,2 to 1,3 in PDT agents 1.9a and 1.9b, respectively, has led to alterations 
in the respective localization (mitochondria vs lysosomes) and efficacy (5:1 ratio) when 
used as PDT agents. The expanded porphyrin MLu 1.10, while similar to MGd both 
structurally and in it’s tumor localizing properties, is therapeutically active as a PDT 
agent.90,91 Several additional porphyrin-type photosensitizers and their targets have been 
discussed in the recent literature.92,93  Nonetheless their specific cellular uptake and sub-
cellular distribution properties (SAR type correlations) are at present poorly understood. 
49,94  
Historically, the high therapeutic activity of MGd has been thought to be due to 
mitochondrial uptake and generation of reactive oxygen species (ROS) such as H2O2 and 
hydroxyl radical (OH.) under therapeutic conditions, triggering apoptosis.49 In fact high 
uptake of MGd in isolated mitochondria has been  demonstrated. 95  
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From the above studies, it can be concluded that lipophilic, cationic porphyrinoids 
generally demonstrate superior tumor uptake and organelle localization. Anionic 
porphyrinoid species are typically observed in lysosomes or near the cell membrane, and 
in the studies carriied out to date, demonstrate lower efficacy. Finally, hydrophilic 
compounds demonstrated the lowest activity. 
 
1.4 CELLULAR IMAGING: PORPHYRINS, TEXAPHYRINS AND XANTHENES 
Of the recent imaging studies involving therapeutic porphyrinoid species, a 
survey of the literature indicates 427 publications for PDT agents and 9 for radiation 
sensitizers. Most of the latter were concerned with Mn porphyrin or MGd. The relatively 
large number of biological fluorescent imaging studies carried out with porphyrins and 
related species reflects their specific uptake by abnormal tissue, long wavelength 
fluorescence (e.g. 650, 720 nm) properties, and adequate fluorescent quantum yield 
(0.09-0.12) all of which facilitate microscopy studies. 96,97  
  The advent of confocal microscopy and charge coupled device (CCD) cameras 
with both higher sensitivity and the ability to perform spectral analysis of images has also 
made it easier to carry out localization studies and helped with differentiation of 
fluorescent species.98,99 Commercial detectors also have good sensitivity in the > 600 nm 
region that corrleates with that of typical porphyrin fluorescence. This is useful since 
fluorescent studies in biological systems using fluorophores that emit above 600 nm 
allows for analysis that is generally free of background interference, whereas in the 400-
500 nm range fluorescence from endogenous species (e.g. the green fluorescent protein 
(GFP)) leads to a high background signal.100 This, in turn, has made it possible to follow 
molecular trafficking events at the sub-cellular level in real time.101 
12 
 The subcellular imaging of MGd is technically challenging due to 
photobleaching, an inherently low fluorescent quantum yield (2.8 x 10-3), and a 
fluorescence emission maximum in the 700-800 nm region where detectors are relatively 
insensitive.49 Imaging studies carried out using Interferometric Fourier Fluorescence 
Microscopy in EMT6 mammary sarcoma cells MGd allowed punctate localization at t = 
4 hours after administation to be noted. The MGd distributed in lysosomes, endoplasmic 
reticulum, and mitochondria, as inferred from comparative organelle staining analysis. 
After 48 hours, MGd was seen in the nucleus in 15% of the cells.102  
 Weakly fluorescent porphyrinoids, such as MGd, can be imaged directly in cells; 
however, due to their low endogenous fluorescence, high sensitivity detectors and 
specialized image processing are required. Species that lack endogenous fluorophores 
must be conjugated to a fluorophore to utilize the aforementioned imaging technique. 
Such fluorescent labeling is, however, expected to provide species that may be used for 
detecting apoptosis, macromolecules, enzyme activity, and imaging the location of 
processes and molecules, etc. It is thus expected to help in the search for new cancer 
drugs.92,103 
Non-fluorescent biomolecule imaging and localization is technically challenging; 
thus, fluorophores with significant fluorescence quantum yields are often appended to 
molecules of interest to improve detection. However, such modification may alter the 
charge on the conjugate or otherwise produce structural changes. The magnitude of 
metabolic changes from “normal,” created by fluorescent tagged substrates is unknown. 
The tagged system, however, is observable. 
The xanthene class of fluorophores (Figure 1.5) are endowed with high quantum 
yields (0.95-0.98). The dyes, FITC, fluorescein, and rhodamine have thus been widely 
used to prepare conjugates for biological molecule localization studies. The anionic 
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species, fluorescein, although a strong fluorophore, has been reported to be rapidly 
excreted from cells by anion pumps.104 Rhodamine demonstrates both selective cancer-
cell localization and PDT activity.105-108 The cationic and slightly lipophilic Rhodamine 
6G demonstrates localization to the mitochondria, whereas the highly lipophilic octadecyl 
rhodamine is retained in cell membranes.109   
 
The xanthene isothiocyanates (i.e. FITC, RITC), are synthetically accessible and 
convenient to use. They react directly with amines and alcohols to form the 
corresponding thioureas and thiocarbamates, respectively. The reactive FITC has been 
used in DNA binding studies. It reacts directly with anilines to generate binding 
fluorophores.110  Rhodamine 6G can be reacted with primary amines to give the amide 
directly.111-114 Rhodamine 6G has also been reacted with linear diamines to give solubile 
fluorophores with a remaining free amine functionality that can be used for further 
conjugation to molecules of interest. 110 The cellular distribution and retention of these 
fluorophores is related to both the charge and lipophilicity of the molecule.  
 
OO OH
OH
O
NCS
ON
H
N
H
O
O
OO OH
OH
O
Cl
FluoresceinFITC Rhodamine 6G
5(6)
ON
H
N
H
O
H
N C18H37
Cl
Rhodamine       
Octadecylamine  
 
Figure 1.5 Xanthene fluorophores used in bioconjugation for imaging studies. 
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 In an elegant combinatorial  study (Figure 1.6), 276 fluorescent styryl quaternary 
cations were synthesized. Of these, 119 demonstrated subcellular localization patterns.115 
In total, 53 demonstrated localization to the mitochondria or nucleus. Structure 1.11 is 
one of the 46 mitochondrially localizing compounds, while structure 1.12 is one of the 
seven nuclear localizing compounds. While, in this series, both compounds are 
structurally similar, more diverse compounds demonstrate mitochindrial uptake, whereas 
the range of nuclear localizing compounds is more limited. Both the mitochondria and 
nucleus possess dual membranes. These sites, from which apoptosis mechanisms are 
triggered, are important sub-cellular localization targets for therapeutic agents. 
 
1.5 ROS GENERATION – PDT, X-RAY, AND REDOX CYCLING 
As discussed above, the specific tumor targeting of porphyrinoids and Reactive 
Oxygen Species (ROS) generating agents is desirable to reduce systemic toxicity. At the 
subcellular level, the location of ROS generating agents is related to efficacy. Especially 
1.11
N
N
N
1.12  
 
Figure 1.6 – Synthesized styryl quaternary cations demonstrating subcellular 
mitochondrial 1.11 and nuclear 1.12 localization.  
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in this context, the concept of catalytic therapeutic agents (not consumed in the 
generation of toxic species) is attractive.   
The significance of sub-cellular localization of these agents is underscored by 
specific ROS species demonstrating high reactivity. For example, hydroxyl radical (HO.), 
has been reported as surviving under cellular conditions only long enough to travel c.a. 
1% of the cancer cell length (0.1 nm/ 10 nm) before reacting with biomolecules.49 Thus, 
the development of therapeutic agents specifically localizating to sites where ROS 
damage triggers apoptosis could, theoretically, increase efficacy.   
Since 1900, therapeutic generation of (ROS) has been extensively studied, using 
both PDT agents and X-ray therapy. Catalytic porphyrinoid ROS generators are 
energetically driven by X-rays (MGd), light (PDT, i.e. Photofrin), or more recently, 
cellular redox systems (MGd).  
 
Porphyrinoid PDT agents provided the first effective method for ROS generation. 
Mechanistically PDT uses light to excite porphyrin molecules and generate singlet 
oxygen, which can serve a precursor for superoxide and (OH .) radicals.49 The high 
absorption of UV light by biological tissues however,  provides a limit to the usefulness 
X-ray + X-ray sensitizer (XRS) → XRS. + e-   
(loss of inner shell electrons) 
(H2O → H2O . + e-) 
(H2O .  + H2O → OH . + H3O+) 
OH. + OH. → H2O2 
OH. + H. →  H2O 
Figure 1.7  Generation of ROS under X-ray conditions. 
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of PDT as a non-invasive technique. The extensive work devoted to producing new 
agents with suitable absorption features has been reviewed.116 There continues to be work 
to develop two-photon techniques with far-UV/near-IR agents, giving tissue transparency 
and adequate energy for PDT generation of ROS.49 
X-ray irradiation (Figure 1.7) is one of the most widely used cancer therapy 
techniques; mechanistically, exposure of atoms to high-energy X-rays results in the 
ejection of inner shell orbital electrons. These solvated electrons react directly with water, 
generating radical species. Most radiation damage is attributed to secondary reactions of 
free radicals.117 Thus, radiolysis primarily produces H3O+, e-, and OH., initiating the 
cascade illustrated in Figure. 1.7.  
With its  low toxicity and high tumor affinity, MGd was considered as a possible 
XRT agent.14 Initially it was proposed that the low affinity of MGd for HO. radicals 
would make it an effective agent.118 The radioenhancing properties of MGd have been 
evaluated in animal models  and reviewed clinically.118-121  
Ascorbate, in combination with MGd via redox cycling, demonstrates enhances 
toxicity and growth inihibition of uterine cancer cell line MES-SA as detected by MTT 
assay. This combination also enhances the radiation response in A549 and MES-SA cells, 
presumably as a result of oxidative stress induced by futile redox cycling.3,122 The highly 
reactive ROS species generated can be detected by UV (benzidine) and 
dichlorofluorescein assays.123 15   
Ascorbate, considered “non-toxic” is attractive as an antioxidant, cancer therapy 
agent, and as an adjuvant. Also, ascorbate has been popularized by Linus Pauling; 
however, it remains controversial as a general dietary supplement, at least at the high 
dosage levels recommended by Pauling.124-128 In fact, both efficacious and adverse effects 
have been reported for ascorbate. In Jurkat cells, H2O2 in the presence of ascorbate leads 
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to a 15-fold increase in DNA lesions, and an increase in both apoptosis and necrosis.129  
Jurkat-ascorbate adjuvant cell studies with the chemotherapeutic agents etoposide, 
melphalan, As2O3, and camptothecin demonstrated no effect for etoposide and 
melphalan. Decreased apoptosis was seen on exposure to As2O3, while camptothecin 
decreased apoptosis, but not necrosis.130,131 
 
Complicating therapeutic use is the instability of ascorbate in aqueous solution 
(Scheme 1.2), a phenomenon that has been discussed in the pharmacology literature and 
specifically evaluated in cell studies.132,133 A spectrophotometric study of the stability of 
ascorbic acid has implicated a decomposition pathway that leads to dehydroascorbate, 
ROS, and diketogulonic acid.132 Studies also indicate that ascorbate is poorly taken up by 
cells. Multiple studies along these lines have used dehydroascorbate (DHA), a product of 
ascorbate oxidation, both because DHA is rapidly taken up by cell glucose transporters 
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Scheme 1.2  Metabolic pathway for the decomposition of ascorbate via DHA  
dimer to DHA under biological conditions. 
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and subsequently reduced to ascorbate, and because it is thought to preclude the 
generation of ROS in culture media.130,131 
 
1.6 DEVELOPMENT OF CHEMOTHERAPEUTIC AGENTS: A TARGETING RATIONALE. 
 
Therapeutic cancer approaches have been researched for more than a century, 
beginning ca. 1900 with non-invasive PDT and X-ray therapy. The anticancer agent 
mustine was developed from “mustard gas” after WW I, reported in clinical trials as early 
as 1942. A more widely publicized story is that development follows the decreased white 
blood cell counts observed in survivors of the sinking of a ship laden with mustard gas, in 
Bari, Italy in 1943. Following this incident it was hypothesized that such agents could be 
used for treating leukemia. 134 The analog carmustine is still in use today, specifically for 
glioblastomas. The folate antagonist methotrexate was developed in the 1950s following 
the observation that cancer patients given folate suppliments fared worse than untreated 
patients. Cisplatin was an accidental discovery in the 1960s. More recently, tumor 
localizing antibody and porphyrinoid experimental agents have been developed. Current 
chemotherapy utilizes a list of approximately 60 clinical agents. 135 Few of these current 
cancer chemotherapy agents localize to tumors. As a consequence, systemic toxicity 
during treatment remains a significant limitation.  
Due to the drawbacks of non-targeting therapeutic agents, considerable effort has 
been devoted to improving localization.  A further incentive  for such studies is that 
targeting can be used to overcome some common resistance mechanisms such as lowered 
uptake, increased excretion, or enhanced detoxification/reduced activation of untargeted 
prodrugs.136,137 Typical conjugates consist of a biomolecule targeting agent, attached to a 
fluorophore for imaging, a cytotoxic agent for chemotherapy, or both.138-140 Therapeutic 
19 
conjugates containing biotin, vitamins, and cholesterol have been evaluated as tumor-
specific conjugates.141,142 Some early tumor localizing conjugates were therapeutically 
inactive because the cytotoxic agent could not be cleaved from the targeting moiety.143,144 
Current conjugates often contain cleavable bonds designed to take into account such 
factors as are needed to release the chemotherapeutic agent under the anticipated 
therapeutic conditions.145,146  
While a number of biomolecules and a few synthetic agents display selective 
tumor uptake as a result of fluid-phase or absorptive endocytosis, synthetic polymers 
such as PEG, while lacking a specific recognition unit can also provide for drug targeting 
agents, utilizing the EPR effect, as previously noted.77  
In an effort to develop texaphyrin-based targeted agents, two approaches have 
been previously reported by this group. Both underscore the importance of 
chemotherapeutic agent release. The first series consisted of methotrexate (MTX) 
chemotherapeutic conjugates.2 While activity was observed in conjugates utilizing a 
readily hydrolyzed ester linkage, the more hydrolytically stable amide linked conjugates 
were inactive. The second series consisted of Pt chemotherapeutic conjugates.147 As will 
be clear from the discussion below, the latter have been less successful than the MTX 
conjugates. 
 
1.7 CONJUGATES FOR TUMOR TARGETING AND PT RELEASE 
 
Several Pt-conjugates have been reported in the literature, synthesized in an 
attempt to develop agents that target tumors and reduce the systemic toxicity often 
encountered with non-specific single agents. These experimental agents reflect a repeated 
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cycle of synthesis, discovery of limitations, and subsequent structural modifications 
leading to further synthetic attempts.  
 
Of particular interest to us were the porphyrin-Pt conjugates, (Figure 1.8).74  
Structures 1.13 and 1.14  were based on a lipophilic hematoporphyrin (Hp) motif of 
porphyrins solubilized with ionic charges or PEG solubilizing substituents.74,148-151 Series 
1.15a - c was based on tetraphenyl porphyrin motif, solubilized with ionic charges.152,153  
In these cases, the non-labile N-Pt conjugates 1.13  and “N-type conjugates,” generally 
lacked activity whereas the ester-Pt conjugates 1.14 and “O-type conjugates” were more 
active. In O-Pt conjugates (1.15b, 1.15c), solubilization with PEG350 or PEG 550 led to 
activity, as did the use of a relatively lipophilic PEG2 conjugate. In series 1.14 appending 
long-chain (n = 17) PEG substituents was found to improve the activity in cell studies, 
albeit only to a point equivalent to that displayed by cisplatin. 150,154   Activity was also 
observed for the cationic O-Pt conjugates (solubilized with either CH2N(CH3)2 or 
CH2N(CH3)3+). Cationic O-type Pt conjugate 1.15c displayed the highest activity of the 
TPP series. 
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Figure 1.8 Porphyrin-Pt conjugates: non-labile (1.13, 1.15a, 1.15c: N-type 
conjugates), labile (1.14, 1.15c: O-type conjugates).  
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 This research group previously synthesized, shown in Figure 1.9, MGd-PEG-
diaminoplatinum and aminosuccinato-platinum conjugates 1.16 - 1.18.147 Unfortunately, 
these systems demonstrated low activity when subject to in vitro biological testing. In 
conjugates 1.16 and 1.17, attachment was effected via piperazine. From previous SAR 
studies of several N-side conjugates, possible spatial limitations for the interaction of the 
Pt(II) centers with DNA were proposed to account for the low activity of 1.16 and 1.17. 
In the case of the aminosuccinate  species, 1.18, the poor performance could be ascribed 
to possible rearangement as discussed below. 
 
Other researchers have developed PEG solubilized malonato-Pt conjugates. In 
these compounds (Fig. 1.10) a malonate moiety is attached to the PEG portion with a 
propyl spacer 1.19,155 or a direct amidomalonate connection 1.20,75 is utilized. The 
species produced in this way demonstrated efficacy. Interestingly, while 1.19 
demonstrated activity, the same compound lacking folate, a non-targeted PEGylated 
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Figure 1.9 Texaphyrin-Pt conjugates: non-labile (1.16, 1.17), labile (1.18) 
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conjugate, formed more DNA adducts than 1.19.155 An amidomalonate-Pt conjugate 1.20, 
containing a Nuclear Localizing Sequence (NLS) to facilitate transport of the molecule to 
the cell nucleus, demonstrated rapid hydrolysis, this premature platinum release (t1/2 = 1 
hour) limited the therapeutic usefulness.75 A polymeric formulation of this 
amidomalonate type of conjugate however, has demonstrated a release rate suitable for 
therapeutic purposes.75,156   
 
 
The classes of Pt conjugates most reported in the  literature (Figure 1.11) are non-
labile diamino coordinating species 1.21, and the labile aminomalonates 1.22, 
amidomalonates 1.23, lipophilic alkyl (or PEG) malonates 1.24, and aspartate complexes 
1.25.  These species have been conjugated to alkanes, long-chain PEG, steroids, bio-
molecules, enzyme inhibitors, and DNA intercalators.73,157,158  
The first synthesized non-labile (Pt-N) conjugates 1.21 generally demonstrated 
poor efficacy when compared to cisplatin. The subsequent platinum aminomalonates 
1.22, while considered more labile, have been reported to rearrange, giving an amine-
bound  (Pt-N) platinum species 1.22a.  Separately, these compounds demonstrated poor 
anticancer activity.159-162 The amidomalonates 1.23 were prone hydrolysis, the specifics 
of the reaction proving to be quite complex.  
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Figure 1.10  Conjugates for targeted Pt-release 
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Analogues of the clinically approved carboplatin, the Pt alkyl malonates 1.24, 
undergo displacement of platinum under aqueous conditions. Alterations in the 
substitution at the malonate β-carbon have been demonstrated to lead to changes in 
efficacy. 73,163-166 The lability of the carboxylates has been shown to be important in 
regulating the stability of these Pt drugs.167 The most active porphyrin conjugates were 
those of the O-Pt type that released the therapeutically active diaquo-type species from 
malonates structurally analogous to 1.24.154  
 
1.8 PLATINUM THERAPEUTIC AGENTS 
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Figure 1.12 Clinical Pt therapeutic agents cisplatin, carboplatin, oxaliplatin, JM216,  
AMD-473, and the active form “Pt diaquo”.  
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Figure 1.11  Types of Pt-complexes used experimentally and as conjugates :  
N-side (1.21), O-side (1.22 - 1.25)
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Inorganic cisplatin (Figure 1.12) is a DNA-modifying agent that forms interstrand 
and intrastrand crosslinks and acts as an inhibitor of both bacterial and mammalian cell 
(tumor) growth.168-170 One of the original inorganic drugs, cisplatin was approved by the 
FDA in 1978. Although cisplatin is used worldwide for the treatment of testicular and 
ovarian cancer, its use is accompanied by significant kidney toxicity, and some tumors 
demonstrate resistance.168,169,171-173 Extensive study has elaborated mechanisms of action, 
profiles, specificity, applications, and patterns of resistance. Some SAR patterns have 
been put forward.174 Numerous analogues of cisplatin have been synthesized (fig. 1.12), 
including carboplatin initially and more recent analogues such as the diaminocyclohexane 
(DACH) derivative oxaliplatin, Pt(IV) diacetate JM216 and picoline derivitive AMD-
473, etc.175-178 These latter species show particular promise in overcoming resistance. All 
of the platinum(II) compounds discussed here contain labile (Cl or CO2-) ligands, which 
give “diaquo,” type species on hydrolysis. The non-labile (NH2R) ligands and their 
significance will be discussed later.  
 In 1989 the FDA approved the clinical use of the second generation drug 
carboplatin, a complex that demonstrates lower kidney toxicity compared to cisplatin.179  
Developed more recently, the third-generation drug oxaliplatin received European 
approval in 1999, and US approval in 2004. This species has proved useful in treating 
resistant colorectal cancer. Both carboplatin and oxaliplatin differ from cisplatin, being 
more lipophilic with cyclobutane-malonate and diaminocyclohexane (DACH) as labile 
and non-labile ligands for the bound Pt(II) centers, respectively. Different systemic 
toxicity is observed in the latter analoges; carboplatin may cause deafness, while 
oxaliplatin has been reported to cause nervous system damage.180 
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The clinically approved drugs cisplatin, carboplatin, and oxallipaltin (Figure 1.13) 
have therapeutic activity, attributed mechanistically to hydrolytic loss of the non-nitrogen 
ligands (chloride or carboxyl), giving initially the mono-aquated species 1.26a, 1.27a, 
and 1.28a respectively. The mono-aquated species, on completion of hydrolysis generate 
the reactive DNA-binding “diaquo” species 1.26b and 1.28b.167,178,181-184  All three parent 
compounds are thus formally prodrugs; the half-life of the prodrugs decreases across the 
series. Thus cisplatin is stable in both phosphate buffered saline (PBS), and plasma. 
Inside the cell, cisplatin demonstrates equilibration of the three above forms, 1.26, 1.26a, 
and 1.26b to a ratio of 44%: 30%: 26%, attributed in part to the lowered chloride level 
(c.a. 100 mM extracellular, 3-20 mM intracellular).  Carboplatin and oxaliplatin undergo 
hydrolysis, with t1/2 = 244 hours and 1.5 hours respectively in saline, decreasing to t1/2 = 
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Figure 1.13 Hydrolysis equilibrium for active Pt therapeutic agents.
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30 hours and 0.25 hours in plasma. Carboplatin hydrolysis (CBDCA loss) has been 
postulated to occur through neutral, acid, and base catalyzed mechanisms.167 This rate of 
hydrolysis, which has been extensively studied, is affected by pH, chloride ion 
concentration in the case of cisplatin, and other nucleophiles.185-188  
The “diaquo” species produced by hydrolysis is highly reactive toward biological 
nitrogen, especially in reaction with cellular DNA, with which it reacts to form GG 
dimers.189 The platinum drugs are known to be reactive with thiol-type compounds such 
as glutathione (GSH), in addition to DNA.190 In the context of Pt agents, resistant cells 
are known to excrete GSH-Pt species.191 Cellular resistance to X-ray irradiation has also 
been correlated with augmented GSH levels.192 
Several platinum-carboxylate analogues of carboplatin, readily synthesized from 
the commercially available carboxylic acids  demonstrate significant therapeutic activity. 
The lipophilic malonates,165 Pt-blues (phthalates),193 and polycarboxylates (i.e. citrate)194-
196 have all been previously reported to demonstrate efficacy in cell culture, and in some 
cases to display reduced systemic toxicity in animal studies, compared to cisplatin. It was 
thus thought these kinds of species would prove useful as Pt releasing linkers that could 
be attached to MGd.  
 
1.9 EXPERIMENTAL N-SIDE SUBSTITUTED PLATINUM ANALOGUES 
While the third-generation drug oxaliplatin is an approved N-side substituted Pt 
compound that demonstrates activity in resistant tumors, efforts continue to be devoted to 
preparing yet improved analogues (Figure 1.14). Lead compounds of this general nature 
include the above transplatin analogue,197the JM-216 bis-succinate analog,198 and three 
pyridine analogs.199-201 Several of these, notably in the pyridine family, demonstrate 
activity against resistant tumors. These compounds being more polar than oxaliplatin may 
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also have higher solubility and improved (or altered) uptake/retention profiles, and 
possibly be cationic at cellular pH. 
 
Previous Pt compounds modified on the inert N-side have served to demonstrate 
that the highest activity is seen when NH3, 1,2-diaminocyclohexane (DACH), small 
alkylamines, and o-phenylene diamine are used to effect the modification.175,202-204 205 
The structures in Fig. 1.14, containing small lipophilic N-side ligands, demonstrate in 
vitro activity in agreement with the SAR predictions. Due to the low water solubility of 
these (alkyl-N)2-Pt complexes, various solubilizing modifications, such as oxygenation, 
have typically led to lower efficacy, heptaplatin being a notable exception.206,207 
Evaluation of these compounds only served to reinforce the lipophilicity and efficacy 
correlation.  
The above mentioned experimental Pt therapeutic drugs (Figure 1.14) are thought 
to act as DNA binding agents. The nucleus and mitichondria, both contain DNA and both 
are compartmentalized within double membranes. For activity as DNA binding agents, 
any Pt therapeutic drugs must reach this compartmenttalized DNA. The lipophilicity and 
efficacy correlation observed in the cell uptake, retention, and PDT studies of the 
previously mentioned rhodamine and porphyrin cationic species appeared similar to the 
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Figure 1.14 Recent experimental cisplatin analogues. 
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trends observed in Pt therapeutic drugs. We hypothesized that the coordination of Pt to 
lipophilic cationic molecules could produce therapeutically active Pt agents. 
 
 
1.10 CATION  MOVEMENT THROUGH MEMBRANES  
   
From numerous imaging studies it is clear that lipophilic cations (Figure. 1.15) 
embed in and move through cellular membranes.  Delocalized lipophilic cations (DLC) 
are known to act as transport agents or toxins and have been proposed for therapeutic use. 
For example NK-529,208 is a fluorescent dye demonstrating localizing (embedding) in 
cell membranes while triphenylphosphonium cation,209-211 demonstrates mitochondrial 
localization and has been proposed as a therapeutic agent carrier.  Toxic membrane 
damaging detergent type cations include dequalinium chloride,212-214 C6-DAP,215 and 
cetylpyridinium,216 which are used as a herbacide,  polymeric antibacterial agent, and 
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Figure 1.15 Cationic compounds demonstrating biological activity. 
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topical disinfectant,  respectively. Therapeutically significant, the aforementined 
rhodamine has demonstated activity in multiple drug resistant (MDR) tumors217 while an 
experimental betaine-Pt compound demonstrates improved efficacy over cisplatin in cell 
studies. 218 
The above mentioned  lipophilic quaternary cationic compounds do not 
specifically target tumors and are either highly toxic or inert, thus they have not generally 
been used therapeutically. If these cations could be conjugated to a targeting moiety, such 
complexes hold potential for localizing in tumors and and subsequently in target 
organelles.  
1.11  SUMMARY AND CONCLUSIONS  
 The experimental expanded porphyrin MGd is currently being tested as a 
therapeutic radiation sensitizer. In the case of both MGd, and the porphyrinoids being 
used or developed for PDT, in vitro tumor localizing activity is typically found to be 
correlated with lipophilicity. At the sub-cellular level, highest activity is typically found 
for cationic molecules. The porphyrinoids and some xanthenes have been utilized as PDT 
agents.  The fluorescence of these compounds has enabled studies of sub-cellular 
localization, which, in turn, are aiding in efforts to develop SAR correlations for various 
therapeutic agents that function with catalytic generation of ROS.  Due to its low 
quantum-yield, sub-cellular localization studies of MGd have required special techniques. 
Recently the porphyrinoids have begun to attract attention for use as localizing 
moieties in conjugates since they could permit the specific uptake or retention of drugs in 
tumors. Such conjugates are particularly likely to be attractive if they could be designed 
such that they could release the therapeutic agents in question. 
Three platinum therapeutic agents are in wide use; however, they suffer from non-
specific toxicity.  Extensive work to develop conjugates has been undertaken. However, 
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activity has been demonstrated in only a few cases.  Significant problems appear to 
plague this approach, involving both molecular (ligand) rearrangements and untoward 
release rates of Pt.  Novel non-labile N-side Pt agents have also been recently developed 
and appear to have higher solubility than the clinically approved oxaliplatin. This N-side 
substitution may improve the solubility of these agents and increase efficacy. Some 
lipophilic cations are also known to demonstrate excellent cell toxicity. Unfortunately, 
metallation generally diminishes their efficacy. From this background we set out to 
develop improved therapeutic agents. 
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Chapter 2:  Motexafin Gadolinium (MGd)-Fluorophore Conjugates  
2.1 INTRODUCTION 
 
The texaphyrins, e.g., motexafin gadolinium (MGd; 1.4) are members of the 
“expanded porphyrin” class of macrocycles. These particular expanded porphyrins have 
demonstrated an ability to coordinate larger metal cations and to concentrate in tumors.  
The additional ability of MGd to generate Reactive Oxygen Species (ROS) under X-ray 
irradiation has resulted in extensive study as an experimental therapeutic agent.41  While 
in vivo localization studies using MGd as an Magnetic Resonance Imaging (MRI) agent 
have proven successful, the subcellular fluorescence imaging of MGd is technically 
challenging.102 In subcellular fluorescence studies of porphyrinoid PDT agents which  
lack the technical challenges of MGd, varying the molecular charge of the PDT agent has 
demonstrated alteration in both toxicity and subcellular localization.89 We hypothesized 
that the synthesis of fluorescent xanthene – MGd conjugates with different molecular 
charges would facilitate evaluation of charge and subcellular localization correlation 
using fluorescent imaging.  
The therapeutic activity of MGd has been ascribed in part to mitochondrial uptake 
and generation of reactive oxygen species (ROS), such as H2O2, via a process of redox 
cycling, thereby triggering apoptosis.219  In fact, the uptake of MGd in isolated 
mitochondria has been demonstrated.95 Further, ascorbate, in combination with MGd, 
was found to engender enhanced toxicity and growth inihibition of uterine cancer cell 
line MES-SA as detected by MTT assay. This ascorbate-MGd combination was also 
found to enhance the radiation response in A549 and MES-SA cells, as were 
subsequently other endogenous electron donors, such as ribonucleotide reductase.3,122,220  
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The localized generation of ROS, which generally act over short distances,49 provides an 
incentive to map out the subcellular localization properties of MGd. 
The subcellular imaging of MGd is technically challenging.  This reflects the fact 
that MGd contains a paramagnetic, gadolinium(III) center and has an inherently low 
fluorescent quantum yield (0.0028%),221 a fluorescence emission maximum in the 700-
800 nm region where detectors are relatively insensitive, and inherent propensity to 
undergo photobleaching.102  In spite of these limitations, cellular imaging studies of MGd 
in EMT6 mammary sarcoma cells could be carried out using liquid Nitrogen cooled CCD 
sensors and image processing to resolve the signals (Interferometric Fourier Fluorescence 
Microscopy).102 This resulted in detection of punctuate fluorescence  after incubating the 
cells for 4 hours in the presence of MGd.  In this study MGd distributed in lysosomes, 
endoplasmic reticulum, and mitochondria, as inferred from comparative organelle 
staining analysis.  After 48 hours, MGd was seen in the nucleus in 15% of the cells.102   
 
While the above study confirmed that MGd can be imaged directly in cells, it also 
served to underscore the potential benefits of MGd analogues that might be more 
fluorescent and hence easier to track at the subcellular level using conventional 
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Figure 2.1.  Fluorophores FITC 2.3, Rhodamine 6G  2.4, and Octadecyl  
Rhodamine 2.5.   
33 
fluorescence microscopy.  In an effort to address this need, we now wish to report the 
synthesis and characterization of two new texaphyrin fluorophore conjugates, namely the 
FITC- and Rhodamine-linked MGd derivatives 2.1 and 2.2.     
The xanthene dyes (Figure 2.1), FITC 2.3 and Rhodamine 6G 2.4 have been 
widely used to prepare conjugates for biological molecule localization studies.104        
Because the fluorescein and rhodamine ions have opposite charge and because any 
structural modification could be potential important, we were curious to see what effect, 
if any, appending a FITC or rhodamine fluorophore had on the subcellular biolocalization 
properties of MGd.  Rhodamine, as a lipophilic delocalized cation has well known 
tendency to accumulate in mitochondria due to their negative membrane potential.222 We 
were also curious whether such modifications would alter the basic in vitro localization.  
Thus, as detailed below, key objectives of the present study were to develop synthetic 
methods for generating fluorescent conjugates, and determine their subcellular 
localization properties. 
 
2.2 EXPERIMENTAL 
 
Previous efforts to elaborate the texaphyrin core with, e.g., redox active or other 
therapeutic agents, have led to the development of two functionalization strategies.  The 
first involves the direct attachment of the modifying group to one of the hydroxypropyl 
substituents, while the other involves replacing one of the glycol groups on the ortho-
phenylenediamine portion of the texaphyrin skeleton with a tether to which the agent in 
question is attached.  We felt both strategies could be applied successfully to the 
development of texaphyrin fluorophore conjugates.  With this consideration in mind, the 
FITC and rhodamine derivatives 2.1 (MGd-FITC) and 2.2 (MGd-Rho) were chosen as 
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specific synthetic targets.  As detailed below, the first of these was prepared via the direct 
functionalization of a preformed MGd core, whereas the second required the preparation 
of an o-phenylenediamine precursor and subsequent synthetic elaboration of the 
texaphyrin macrocycle. 
 
As shown in Scheme 2.1, conjugate 2.1 could be prepared starting from MGd 1.4 
and FITC 2.3 (available as an 85:15 mixture of the 5 and 6 substituted isomers).  Mixing 
these two species in hot acetonitrile gave the expected MGd mono-FITC conjugate 2.1.223  
Purification of product 2.1 was effected on a reverse phase tC-18 RP Sep-Pak column. 
HPLC analysis of the purified product was consistent with the presence of two MGd-
FITC thiocarbamate conjugates, in the expected isomer 85:15 ratio dictated by the 5(6)-
FITC starting material(UV472: 93.08% = 12.56% + 80.52% at Tr = 8.63 min, 9.57 min, 
respectively). The material was additionally characterized by HRMS and elemental 
analysis. The FITC conjugate 2.1 demonstrated water solubility of less than 0.01 mg/ml 
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Scheme 2.1.  Synthesis of FITC-MGd conjugate 2.1 and control compound 2.6. 
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(UV470 basis in deionized water). As a control for the imaging studies, the published 
3,5-dimethylaniline-FITC urea 2.6 was also prepared. 
The synthesis of compound 2.2, was effected starting from a  solubilized 
dinitrobenzoic acid derivitive 2.7, and the leuko form of a highly water soluble derivative 
of rhodamine 6G, 2.8, both prepared by published procedures.111,147,224   Thus the 
synthesis of 2.9 was effected by activation of 2.7 as the NHS derivative, mediated by 
DCC, followed by reaction with 2.8 (1.2 equiv.) as the leuko form. After stirring 24 hours 
the reaction was quenched in water, extracted into methylene chloride, and purified by 
flash chromatography on mildly deactivated silica gel (CH2Cl2/MeOH/NH3) to give the  
amide 2.9. The nitro groups of 2.9, were then catalytically reduced (Pd/C, H2) in 
methanol, to produce the unstable diamine. The methanolic solution was then filtered 
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Scheme 2.2 Synthesis of MGd-Rhodamine conjugate, 2.2. 
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through Celite to remove the catalyst and immediately reacted with dialdehyde 2.10 at 50 
oC in the presence of acetic acid catalyst to give the cyclized “sp3” texaphyrin 
intermediate 2.11. The solution was evaporated to give a red oil. Separately, a solution of 
Gd(OAc)3 (1.5 equiv.) in methanol with triethylamine (11 equiv.) was saturated with air 
by sparging for 10 minutes. To this solution was added the “sp3” texaphyrin intermediate 
2.11, redissolved in a minimal amount of methanol. The resulting solution was heated to 
50 oC for 12 h to give the crude metallated conjugate 2.2. Purification was effected in two 
stages. First the crude material was purified by flash chromatography on deactivated silca 
gel (CH2Cl2/MeOH/HOAc). The product-containing fractions were combined, 
evaporated, and further purified by reverse phase chromatography on tC18 SPE 
cartridges. HPLC analysis of the purified product demonstated predominantly a single 
product (UV472: 95.18%, Tr = 12.85 min). The material was additionally characterized by 
HRMS and elemental analysis. 
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2.3 SPECTROSCOPIC AND PHOTOPHYSICAL STUDIES 
 
The fluorophore conjugate intermediates were additionally characterized by UV-
visible and fluorescence spectroscopy for determination of extinction coefficient and 
quantum yield.  This latter was important because  MGd contains a paramagentic Gd(III) 
center that could potentially quench the fluorescence of an appended fluorophore.  
The electronic spectra of the MGd-FITC and MGd-Rho conjugates, 2.1 and 2.2, 
recorded in methanol, are shown in Figure 2.2.  As can seen by inspection of this figure, 
there is little difference in the spectra of the conjugates compared to that of MGd.  The 
expected texaphyrin-derived Soret and Q bands were observed at ca. 470 and 750 nm, 
respectively.  Although some broadening in these bands is seen, no features specifically 
ascribable to the FITC and rhodamine subunits were observed 
 
 
Figure 2.2. Electronic spectra of MGd 1.4 (□) and its fluorescent derivatives MGd-FITC 
2.1 (■)and MGd-Rhodamine 2.2 (●) as recorded in methanol.   
38 
The methanol solutions of 2.1 and 2.2 used to record the UV-visible spectrum 
were found to lack any significant absorbance that can be attributed to the attached 
fluorophores. This is not unexpected since both fluorophores are in their non-ionized 
form and in this state they do not absorb strongly. To these solutions was added dilute 
base (MGd-FITC 2.1) or acid (MGd-Rho 2.2). This gave much more strongly absorbing 
species, as can be seen in Figure 2.3, in agreement with conversion of the xanthenes to 
their ionized forms.  For instance, the intensity of the absorbances at 470 and 495 nm in 
the spectrum of the FITC conjugate 2.1  (also recorded in methanol) were seen to 
increase to ca. 149% and 80%, respectively, as compared to the unionized 470 nm 
absorbance illustrated in Figure 2.4.  Likewise, a methanolic solution of the MGd-Rho 
conjugate 2.2 was seen to turn red upon acidification amd there was the appearance of a 
new 530 nm peak in the electronic spectrum, characteriztic of rhodamine, at c.a. 80% of 
the intensity of the 470 nm MGd absorbance observed for the unionized form in Figure 
 
 
Figure 2.3. Electronic spectra of MGd 1.4 (□), MGd-FITC 2.1 (■) (+NaOH), 
and MGd-Rhodamine 2.2 (●) (+HCl) as recorded in methanol.   
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2.4. Thus the ionized xanthene conjugates 2.1 and 2.2, absorbing at 495nm and 530 nm 
were in agreement with the reported 500 nm and 530 nm respectively for ionized 
fluorescein and rhodamine. 
 
The quantum yields of MGd-FITC and MGd-Rho (Figure 2.4) were determined 
by utilizing standards with known quantum yields (sodium fluorescein Φf  = 0.92, 
Rhodamine 6G, Φf  = 0.95, MGd Φf = 2.8 x 10-3).225,226 Using an otherwise uncorrected 
fluorimeter and a published procedure,227 the quantum yields of all fluorophores were 
determined in comparison with literature compounds, at reported excitation wavelengths 
.227-231 Due to the difference in the Φf, measurements were performed at 50 μM (2 nm slit 
width) and 200 μM (0.5 nm slit width) for the xanthene and MGd fluorophore Φf, 
respectively. The published fluorescence excitation wavelengths of MGd, fluorescein and 
rhodamine (473nm, 456nm, and 480 nm respectively) are grouped closely together.225,232 
0
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Figure 2.4. Quantum Yield determination for unconjugated (black bars) and 
conjugated (white bars) fluorophores: Fluorescein, Rhodamine, MGd , and their 
conjugates as recorded in methanol.   
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We hypothesized that co-excitation of the fluorophores was thus possible for the 
conjugates.  
The results of the quantum yield (Φf) determination for the conjugates revealed a 
significant decrease in the Φf for the appended fluorophores (Φf  = 0.27 and 0.21 for 
FITC and Rhodamine conjugates, respectively). Smaller variations were ascribable to the 
fluorescence of the MGd core (Φf  =  2.7 x 10-3 and 2.1 x 10-3 for the MGd - FITC and 
MGd - Rhodamine conjugates, respectively).  Specifically, the MGd-derived fluorescence 
Φf in the MGd-FITC, and MGd-Rho conjugates 2.1 and 2.2, decreased to 76% and 83% 
of that recorded for free MGd, 1.4.  In contrast, the Φf of the FITC and rhodamine 
fluorophores in the conjugates 2.1 and 2.2 were only 25% and 20%, respectively, of the 
corresponding non-conjugated values. The Φf results obtained for the conjugated 
xanthene fluorophores is in broad agreement with  Φf = 0.13 – 0.18  reported for 
fluorescein-peptide conjugates,227 thus the decrease in Φf  may not be simply a result of 
proximity to Gd.  
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2.4 IMAGING AND CYTOXICITY STUDIES IN A549 CELLS 
 
 
Figure 2.5. Legend: Rhodamine leakover control study showing two different photographs of A549 
cells that were loaded with Mitotracker Red, a rhodamine derivative. The images on the left side are 
taken using the “Rhodamine” filter set whereas the images on the right side are taken using the MGd 
filter set.  
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Figure 2.6. Legend: Intracellular localization of MGd and its conjugates. 1A-C are images of A549 
cells loaded with Lysotracker and unconjugated MGd. 1A shows an image taken using the 
Lysotracker filter set whereas 1B is a fluorescence image taken using the MGd filter set. 1C shows 
the overlay of the Lysotracker image (red) and the MGd image (green). 2A-C  are images of A549 
cells loaded with mitotracker and unconjugated MGd. 2A shows an image of mitotracker obtained 
using the rhodamine filter set whereas 2B shows a fluorescence image of the same cell using the 
MGd filter set. 2C shows the overlay with mitotracker (red) and MGd (green). 3A-C are images of 
A549 cells loaded with the MGd-FITC conjugate using the fluorescein (3A) or MGd (3B) filter sets. 
3C shows the overlay of the fluorescein filter image (green) and the MGd filter image (red). 4A-C 
are images of A549 cells loaded with MGd-Rho conjugate using the rhodamine or MGd filter sets. 
4a shows a fluorescence image using the rhodamine filter set whereas 3B shows an image of the 
same cell obtained using the MGd filter set. 4C shows the overlay of the rhodamine image (red) and 
the MGd image (green).  
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Figure 2.7. Legend: Colorized fluorescence microscopy photographs of A549 cells incubated with 
organelle stains, MGd and MGd-conjugates. 1A-F are control organelle stains. Fluorescence images
of cells incubated with MGd-FITC 2.1, were taken using the FITC filter set (2a) and the MGd filter 
set (2b). Image 2c shows an overlay of 2a and 2b. Fluorescence images of cells incubated with 
MGd-Rho 2.2, were taken using the Rhodamine filter set (3a) and the MGd filter set (3b). Image 3c
shows an overlay of 3a and 3b. 
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The texaphyrin conjugates were incubated with A549 lung cell lines to study their 
uptake and distribution patterns. Initially, imaging of MGd-FITC 2.1 was attempted using 
confocal microscopy due to the higher resolution of these instruments, but in this case, no 
signal could be obtained from MGd alone; only the xanthene portion was detectable. 
Since an important goal of this study was to obtain colocalized images of MGd 
fluorescence and rhodamine or fluorescein fluorescence in their respective conjugates, all 
further studies were carried out using wide field microscopy. 
Fluorescence imaging studies were performed using a wide-field fluorescence 
microscopy and ccd camera. The imaging studies were performed using commercial 
fluorescein and rhodamine filter sets to image the xanthene portion of the conjugates. The 
MGd imaging was performed using a custom excitation filter (470 nm  +/- 20 nm 
excitation filter and    700+ nm long pass emission filter), obtained from Chroma.® This 
filter was chosen to reduce emission from either the rhodamine or fluorescein 
components of the conjugates and allow selective imaging of the texaphryn fluorescence 
or the texaphryn component of the rhodamine and fluorescein conjugates. In a control 
bleedover experiment using Mitotracker (Figure 2.5), only a small amount of 
fluorescence attributable to rhodamine species was observed when using the MGd 
imaging custom filter. Additional images of the A549 cells using fluorescent organelle 
stains (Figure 2.6, 1a-f) were obtained to act as localization controls, fluorescein controls 
1e and 1f utilized fluorescein and 3,5-dimethylaniline-FITC to demonstrate localization 
of unconjugated fluorescein species. Dual labelling images of the A549 cells using MGd 
and fluorescent organelle stains (Figure 2.7, 1a-c, 2a-c) were obtained as additional 
controls. 
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The study in Figure 2.6 and showed that MGd 1.4, MGd-FITC 2.1 or MGd-Rho 
2.2 at 5 μM was rapidly internalized by cells. Specifically, cellular uptake of MGd and 
Lysotracker; MGd and Mitotracker, MGd-FITC 2.1, and MGd-Rho 2.2 is demonstrated 
in the control dual labeling studies (Fig. 2.6, 1A-1C through 4A-C respectively). In the 
dual labeling studies with MGd, Lysotracker, and Mitotracker (image 1A, 1B and 2A, 
2B), differential  punctate distribution was observed. In the conjugate studies with 2 and 
3, some particulates were observed in the media, presumably precipitated conjugate, 
fluorescent only with the long pass filter. 
MGd and its fluorescein conjugate both show a tendency to accumulate in the 
lysosomes as indicated from long pass filter images 1B and 2B, respectively. This image 
is more intense with the fluorescein conjugate. The images generated from the two 
fluorophores of the MGd-fluorescein conjugate show lysosomal colocalization, with 
some differences depending on the filter set used. In images of dividing cells (Figure 2.6, 
3a-c and Figure 2.7, 2a-c (bottom photos)) generated from the two fluorophores of the 
MGd-fluorescein conjugate show nuclear colocalization, with some differences 
depending on the filter set used. Using the MGd filter set, weak nuclear fluorescence is 
observed (Figure 2.6, 3b) along with the punctate cytoplasmic distribution, typical of the 
MGd compounds as in image in Figure 2.7, 1B. The MGd-fluorescein image overlay 
shows a nuclear pattern of localization, different from either fluorescein alone or the 
dimethylaniline-FITC control. 
The images from the two fluorophores of the MGd-Rho conjugate also differ 
depending on the filter set. When using the rhodamine filter set, intense cytoplasmic 
staining is observed. Using the MGd filter set, weak cytoplasmic fluorescence is observed 
(image Figure 2.7, 4B), along with intense punctate spots. A likely explanation is that 
rhodamine fluorescence is pH, and thus, organelle dependent. This was also observed  in 
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the particulates with no rhodamine fluorescence detected colocalizing with either 
intracellular or extracellular punctate spots. From these images it appears that MGd and 
its rhodamine conjugate can gain entry to mitochondria. This is in agreement with a 
number of compounds bearing a delocalized positive charge which tend to accumulate in 
mitochondria. The rhodamines are often employed as a vital stain for this organelle. Thus 
rapid localization is thus demonstrated by both these conjugates, conjugate 2.1 appearing 
in the lysosomes, and in the nucleus of dividing cells, while 2.2 is observed in the 
mitochondria.  
 
2.6 DISCUSSION  
In this paper we have described the synthesis of two fluorescent MGd conjugates.  
The first of the these, the FITC-based system 2.1, was prepared from MGd via a direct 
coupling procedure, whereas the corresponding rhodamine conjugate, 2.2, required a 
more directed synthesis procedure.  Both conjugates were characterized using standard 
means. The subcellular localization properties were then tested using fluorescence 
microscopy and MTT assays. We have confirmed our hypothesis that the two conjugates, 
differing in xanthene fluorophores and charge, could demostrate differential cellular 
distribution.  
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2.7 Experimental Section 
 
Materials. Unless otherwise noted, all reagents were obtained from commercial 
suppliers and used without further purification. Solvents were dried over molecular sieves 
except dichloromethane, which was dried over CaH2.  Methanol used in sp3-texaphyrin 
syntheses was degassed by purging with argon for 5 minutes.  Methanol used in the sp2-
texaphyrin syntheses (MGd cyclization and metallation) was oxygenated by purging with 
air for 5-10 minutes, with additional purging being carried out during the reaction period 
for large scale preparations. The intermediate tripyrrane-dialdehyde 2.10 (2,5-bis[(5-
formyl-3-hydroxypropyl-4-methylpyrrol-2-yl) methyl]-3,4-diethylpyrrole) was supplied 
by Pharmacyclics, Inc.  The (2-{2-[2-(2-Methoxy-ethoxy)-ethoxy]-ethoxy}-4,5-dinitro-
phenoxy)-acetic acid 2.7 was prepared by literature methods.147 The Gd(OAc)3.xH2O 
was supplied by Strem Chemical Company. 
Chromatography. Merck type 60 (230-400 mesh) silica gel was used for column 
chromatography.  For small-scale work-up Sep-Pak cartridges were purchased from 
Waters in 0.5-20 gram sizes of C-18 or silica. TLC was carried out using the conditions 
noted below using Whatman K6F aluminum backed silica gel plates.  
HPLC analyses. HPLC analyses were performed on a Beckman or Shimadzu 
Analytical/Preparative HPLC system with a Zorbax XDB 5 μM 5 x 100 mm column. A 
0.1% TFA (or 33mM NH4OAc) aqueous phase against acetonitrile (ACN) gradient (10-
95% over 15 minutes followed by 5 minutes at 95% acetonitrile) was used for analysis of 
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the MGd fluorophore conjugates. All 1H, and 13C NMR spectra were measured with a 
Varian 300 MHz or Varian Mercury 400 (400 MHz.) spectrometer in CDCl3, D2O, 
CD3OD or D7-dmf. The NMR chemical shifts are reported in ppm relative to the solvent. 
Low resolution and high resolution electrospray mass spectrometry (ESI MS) were 
performed with a Thermo Finnigan LTQ  and Qq-FTICR (7 Telsa) instruments, 
respectively. Mass spectrometry (LRMS, HRMS) was carried out by the University of 
Texas at Austin Mass Spectrometry Facility. Elemental analyses were performed by 
Midwest Microlabs Inc. Electronic spectra were recorded on a Beckman DU-7 
spectrophotometer.  
Fluorescence and Quantum Yield: Measurements were performed according to 
published procedures.227 Briefly, the electronic spectra were measured and the 
absorbance adjusted to c.a. 1.0 AU (0.9-1.1). The quantum yields were then measured on 
a Jobin Ybon fluorimeter. The xanthene Φf FITC was measured at 50 μM, 0.5 nm slit 
width, λex/em 456/470-650 nm, The xanthene Φf Rho was measured at 50 μM, 0.5 nm slit 
width, λex/em 480/500-700 nm, the MGd Φf was measured at 200 μM, 2 nm slit width, 
λex/em 473/650-850 nm. The fluorescence emission for each was integrated over the noted 
range and compared to the commercial xanthene fluorophore or MGd. 
Chromatography: TLC, Flash, and SPE  
TLC - Silica gel TLC of organic soluble samples commonly used EtOAc/hexanes 
or DCM as the eluents. The water solubilized PEGylated intermediates were 
chromatographed using 9:1 DCM:MeOH with HOAc or NH3 to further deactivate the 
silica gel unless otherwise indicated. Silica gel chromatography of the texaphyrins 
required 9:1:0.1 DCM:MeOH:HOAc as the eluent.  
Flash Chromatography - For the MGd mono-substituted complexes 
chromatography was typically performed by loading up to 1000mg MGd as a DCM 
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solution on 75 cc pre-packed silica gel (1" diameter column) and eluting with 200-400 ml 
DCM, followed by 200-400 ml DCM/0.1-0.2% HOAc containing 5% MeOH, followed 
by the same solution at 10-40% MeOH.  This elutes the first small red and pale green 
impurities.  The main fraction is eluted with 400-800 ml DCM/HOAc solution containing 
15% MeOH.  Relevant fractions are collected as 100-200 ml aliquots.  Relevant fractions 
can be re-chromatographed on 100 cc silica gel by diluting to 5% MeOH and loading 
directly onto the column.  Elution with DCM/0.1% HOAc at 10% MeOH removes the 
trace red and green impurities and the main product fractions are removed at a gradient of 
15-40% MeOH in DCM/HOAc with 400-600 ml solvent.  
SPE - The MGd conjugates could also be purified on RP-tC18 SPE (Waters Sep-
Pak) columns using gradients of MeOH or ACN against aqueous buffer (33mM 
NH4OAc). 
Synthesis of MGd-FITC (carbamate). 2.1 To a solution of MGd (1130 mg, 0.98 
mM) in ACN (150 ml) was added fluorescein isothiocyanate (FITC) (380 mg,  0.98 
mMol). The solution was  stirred at 50 oC for 72 hours, followed by evaporation to 
provide the crude product (1.31g, 91%). Purification of 1000 mg was effected by 
dissolving the solid in DCM/MeOH (25 ml, 9:1) and adding  acetonitrile/0.1 M NH4OAc 
buffer/HOAc (80 ml 4/1/1) followed by evaporation at 60 oC to remove the DCM. The 
residual solution was filtered to remove the insoluble material and the filtrate was diluted 
with water (1:1). This aqueous solution was divided into 3 portions and each loaded  on a 
C-18 SPE column (10 g). Each loaded column was first washed with 
acetonitrile/buffer/water (4/1/1), to remove impurities, followed by  acetonitrile/buffer 
(3:2) to remove MGd. The MGd-FITC product was then eluted with acetonitrile/buffer 
(4:1).  The resulting product solutions were combined, diluted with buffer (1:1) and 
reloaded on the C-18 SPE column. The column was washed with water (20 ml), 
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acetonitrile (30 ml), and the product was then eluted with 98/2 (MeOH/HOAc).  
Evaporation, tituration with Et2O, and drying under high vacuum provided a green solid 
(234 mg, 15 %). HPLC (472 nm): 93.08%, a mixture of the 5(6) isomers. (Tr = 8.63; 
12.56%); (Tr = 9.57; 80.52%). MS (EI) (M-2 OAc)+ 1418. HRMS(EI)+ calculated for 
C69H76Gd[158]N6O15S (M-2 OAc) 1418.4330, found 1418.4314. UV (dilute into MeOH/ 
2% HOAc) λmax (log ε): 283 (4.53),  414 sh. (4.57), 474 (4.93), 740 (4.46). Φf MGd = 
0.0021 (200 μM, 2 nm slit width, λex/em 473/650-850 nm), Φf FITC = 0.27 (50 μM, 0.5 nm 
slit width, λex/em 456/470-650 nm). Anal. Calcd for MGd-FITC.5H2O: C 57.05%; H 
5.38%; N 5.47%; S 2.09%. Found: C 57.26%; H 5.23%; N 5.17%; S 2.03%. The extreme 
line broadening due to the paramagnetic Gd precluded NMR analysis of the MGd 
conjugates. However, HPLC analyses, MS studies, and UV-Vis spectroscopic studies 
were carried out. 
Synthesis of Rhodamine amide 2.8, N-(3-{2-[2-(3-Amino-propoxy)-ethoxy]-
ethoxy}-propyl)-2-(6-ethylamino-3-ethylimino-2,7-dimethyl-3H-xanthen-9-yl)-
benzamide. This compound was prepared according to a modification of a published 
procedure111,224,227. Briefly, to a solution of Rhodamine 6G (1.88 g, 3.9 mMol) in DMF 
(75 ml was added 4,7,10 Trioxa-1,13-tridecanediamine (3.0 ml, 13.6 mMol). The 
resulting solution was held at 60 oC for 24 hours. Evaporation of the DMF and 
purification by flash chromatography over basic alumina (DCM/MeOH gradient 0-15%) 
provided the product (1.82 g, 75%) as an oil.  
By HPLC analysis the material eluted as two peaks, agreeing with a protonated 
(10.78 min, high 529 nm UV absorption) and non-protonated (11.47 min.) form, the 
ratios interconverting dependent upon pH (respective HPLC retention times and UV 
spectra are identical).  
51 
HPLC (529 nm): Tr 10.78 min = 66.53%, 11.47 min = 25.45% (the total area % of 
protonated and non-protonated forms as noted above was 91.98%); OH- pre-treatment: 
10.78 min = 50.18%, 11.47 min = 38.54% (total 88.72%). TLC: (silica-5/1/0.05 
DCM/MeOH/NH3) Rf=0.5. 1H NMR (400 MHz, 6d-DMSO/D2O) 1.25 (6H, t), 1.60-1.72 
(4H, m), 1.84 (6H, s), 3.04 (2H, t), 3.10-3.26 (10H, m), 3.40-3.57 (15H, m), 6.17 (2H, s), 
6.31 (2H, s), 6.93 (1H, m), 7.48 (1H, m), 7.82 (1H, m). MS (CI) (M+2H)+ 618. 
HRMS(CI) calculated for C36H49N4O5 617.3703, found 617.3709  
Synthesis of Dinitrobenzene-Rhodamine amide 2.9, N-(3-{2-[2-(3-Amino-
propoxy)-ethoxy]-ethoxy}-propyl)-2-(6-ethylamino-3-ethylimino-2,7-dimethyl-3H -
xanthen-9-yl)-benzamide. To a solution of 2.7 (0.5 g, 1.24 mMol) in DMF (5 ml) and N-
hydroxysuccinimide (0.14 g, 1.2 mMol) was added DCC (0.25 g, 1.2 mMol) in DCM (2 
ml). The reaction was stirred for 30 minutes, after which 2.8 (0.76 g, 1.23 mMol) was 
added. The solution was was stirred overnight.  Purification of the product was effected 
by flash silica gel chromatography (9/1/0.05 DCM/MeOH/NH3) twice to provide the 
product 2.9 (0.39 g, 32%). Material could also be purified on tC-18 SPE cartridges with 
TFA(0.1%)/ACN gradient (80/20 to 20/80) and the purified fractions partitioned between 
DCM and 5% aq. NaHCO3. The DCM solution was dried over K2CO3 and evaporated to 
give a clear oil. HPLC (528 nm): Tr = 12.87min, 14.92 min (total 96.12%); 28.20%, 
67.92% respectively; Tr (pre-treatment with 3N HCl):12.75 min = 93.70% TLC: Rf=0.6 
(5/1/0.05 DCM/MeOH/NH3). 1H NMR(400 MHz, CDCl3) δ 1.32 (6H, t,  7.2 Hz), 1.40 
(2H, p), 1.80 (2H, p), 1.89 (6H, s), 3.13-3.24 (8H, m), 3.35 (2H, s), 3.36-3.37 (2H, m), 
3.43 (2H, q, J = 6.2 Hz), 3.48-3.54 (12H, m), 3.60-3.65 (4H, m), 3.68-3.70 (2H, m), 3.90 
(2H, t, J = 4.4 Hz), 4.34 (2H, t, J = 4.8 Hz), 4.62 (2H, s), 6.21 (2H, s), 6.32 (2H, s), 7.02 
(1H, m), 7.18 (1H, t, J = 5.5 Hz), 7.41-7.45 (3H, m), 7.53 (1H, s), 7.88 (1H, m). MS (CI) 
(M)+ 1003. HRMS(CI) calculated for C51H67N6O15 1003.4664, found 1003.4627. Anal. 
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Calcd for C51H67N6O15: C 61.00%; H 6.73%; N 8.37%. Found  C 54.74%; H 5.37%; N 
5.95%. 
Synthesis of sp3-texaphyrin-rhodamine conjugate 2.11 A solution of 2.9 (0.39 
g, 0.39 mMol) in EtOH (50 ml) with H2O (2 ml) and 10% Pd/C (0.1 g), was 
hydrogenated for 24 hours.  The resulting solution with the addition of  conc. HCl (1 ml) 
was filtered through celite and the cake washed with ethanol. The filtrate was added to a 
solution of  2.10 (0.19 g, 0.40 mMol) in MeOH (100 ml) under argon.  The solution was 
held at 50 oC for 12 hours, turning deep red as the reaction progressed.  Evaporation gave 
the sp3TxRh.3HCl 2.11 product (0.57 g, 98%). MS (EI) (M+2H)+2 695. HRMS(EI) 
calculated for C79H106N9O13 1388.7910, found 1388.7890. UV (MeOH/ 2% HOAc) λ, 
max.: 371, 492 sh, 529. 
Synthesis of  MGd-rhodamine conjugate 2.2. A solution of the above 2.11 (0.24 
g, 0.16 mMol), Et3N (0.25 ml, 11 equiv.) and Gd(OAc)3 (0.10 g, 1.5 equiv.) in MeOH 
(100 ml) was saturated with air, by sparging for 10 minutes, and heated to 50 oC in air for 
12 hours. The resulting solution was evaporated to dryness to give 0.31 g, of a solid. 
Purification was effected by flash silica gel chromatography (DCM/1% HOAc with a 
MeOH gradient: 0-25% to remove impurities, 40% MeOH to elute the product) to give a 
green solid. The material was further purified by dissolving the sample in a solution of 6 
ml ACN and 0.5 ml HOAc, dilution 1:1 with NH4OAc buffer  (0.1 M NH4OAc pH=4.3) 
and loading on a C-18 SPE cartridge (10g).  The column was washed with 20-40% ACN 
to remove impurities and the product was eluted with 60% ACN / 40% NH4OAc buffer. 
This solution was diluted 1:1 with buffer, again loaded onto the C-18 column and eluted 
with 75% ACN, the resulting solution was evaporated and dried in high vacuum.  
Dissolving in 1 ml MeOH, dilution with 4 ml water and dialysis against water (1000 
mwco) gave no change in the conductivity of the water (NH4OAc sublimes under high 
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vacuum). Final evaporation gave a green solid 2.2 (45 mg, 7%). HPLC (472): RT 12.85 
min; 95.18%.  Acidification with HCl (3N, 1% v/v) resulted in the appearance of two 
peaks in the HPLC, in agreement with conversion of the leuko form, presumably to the 
colored ioinized form: HPLC (472): RT 12.60 min; 49.69%: RT 15.10 min; 45.70%. MS 
(EI) (M – OAc )+ 1600, (M – 2 OAc +H)+ 1542. HRMS(EI) calculated for 
C79H101N9O13Gd[155] 1538.6745, found 1538.6749. UV (MeOH/ 2% HOAc) λmax (log 
E): 308 (4.41),  420 sh. (4.58), 470 (4.94), 743 (4.48). ΦfMGd= 0.0023, (200 μM, 50 μM 
respectively); MGd (λex = 473, λem = 650-850), ΦfRho = 0.21 (λex = 480, λem = 500-
700). Anal. Calcd for C83H106N9O17Gd: C 60.09%; H 6.44%; N 7.60%; O 16.39%. Found 
C 60.40%; H 6.51%; N 7.67%; O 16.26%} 
Synthesis of 3,5-dimethylaniline-FITC (thiourea), 2.6 5-[3-(3,5-Dimethyl-
phenyl)-thioureido]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-benzoic acid.110 To a solution 
of 3,5-dimethylaniline  (80 mg, 0.66 mM) in EtOH (6 ml) was added FITC (250 mg,  
0.64 mMol).  The solution was stirred at 25 oC for 24 hours. The solution was partitioned 
between HCl (40 ml, 3N) and DCM:MeOH (100 ml, 9:1), washed with water, brine, and 
dried over MgSO4. Evaporation followed by flash chromatography purification over 
silica gel to provide the product (60 mg, 18%). HPLC (445 nm): Tr 12.77 min.  98.36%. 
1H NMR(400 MHz, d6- DMSO) δ 2.23 (s, 6H), 6.56 (s, 4H), 6.66 (s, 2H), 6.79 (s, 1H), 
7.02 (s, 2H), 7.16 (d, 8.0 Hz, 1H), 7.75 (d, 8.4Hz, 1H), 8.10 (s, 1H), 9.97 (s, 1H) 10.08 
(d, 1H), 10.11 (s, 2H). MS(CI) (M-H)- 509. UV (DMSO solution diluted into MeOH) 
λmax (log ε): 277 (5.54),  453(4.97), 479 (4.96). UV (DMSO solution diluted into MeOH, 
2% (by volume) 0.1 N NaOH added) λmax (log ε): 284 (5.52),  496(5.89). 
Electronic Spectra and Quantum Yield Determination: The electronic spectra of 
the MGd-fluorophore conjugates 2 and 3 at 1.17 x 10-5 M and 1.15 x 10-5 M respectively 
in methanol solution containing acetic acid (0.35 M) gave a UV absorption of 1.0 (+ 
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10%). Conversion to the fluorescent zwitterionic forms was effected by altering the pH of 
the methanolic solutions (with 0.1% v/v; 0.1 N NaOH and 3 N HCl respectively). These 
solutions were then diluted for the fluorescence studies. The quantum yields of the MGd 
and xanthene portions of the conjugates respectively were determined at 2 x 10-7 M (2 nm 
slit width) and 5 x 10-8 M (0.5 nm slit width) respectively. 
Imaging Studies and Cytotoxicity Measurements in A549 Lung Cancer Cells 
Fluorescence microscopy was performed using a Nikon Diaphot 200 microscope 
with fluorescein and rhodamine filter cubes. MGd fluorescence was observed using a 
custom filter set (Chroma Technology Corp.) Consisting of  a D470/40x excitation filter, 
a 495dclp dichoric mirror, and an E700lp emission filter.  
The human lung carcinoma cell line A-549 was obtained from ATCC and 
cultured in DMEM supplemented with 10% FBS and streptomycin/penicillin mixture. 
Cell lines were maintained as monolayer cultures in plastic culture flasks grown at 37oC 
in a humidified atmosphere of 5% CO2/95% air.  
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Chapter 3: Motexafin Gadolinium (MGd)-Malonato-Platinum 
compounds. 
3.1 INTRODUCTION 
 
Although cisplatin (Fig. 3.1) is used worldwide for the treatment of testicular and 
ovarian cancer, its use is accompanied by significant kidney toxicity.168,169,171-173 
Carboplatin and oxaliplatin are also widely used cancer therapeutic agents but they also 
show systemic toxicity due to non-specific tissue distribution. The MGd-Pt conjugates 
previously prepared have demonstrated poor efficacy in cell studies.147 As MGd 
demonstrates both low toxicity and high tumor specificity in vivo, we hypothesized that 
MGd-Pt conjugates with more “carboplatin-like,” coordination, e.g. malonates, could 
prove more active than the MGd-Pt conjugates to date.   
Many strategies have been used to increase their tumor specificity, including 
structural modifications to the compound or by conjugation to antibodies, folate, PEG, 
and porphyrins. In addition, considerable effort has been directed at improving the 
performance of these compounds in terms of their ability to deliver active forms of Pt to 
cells.147,155,233 Extensive study has elaborated mechanisms of action, profiles, specificity, 
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Figure 3.1 Structure of Pt therapeutic agents cisplatin, carboplatin,  
oxaliplatin, and active form “Pt diaquo.” 
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applications, and patterns of resistance. These three approved drugs have therapeutic 
activity, attributed mechanistically to hydrolytic loss of the non-nitrogen ligands 
(chloride or carboxyl), giving initially a mono-aquated species. The mono-aquated 
species, on completion of hydrolysis and loss of the O-side ligand, generates the reactive 
DNA-binding “Pt diaquo” species.167,178,181-184   
Several Pt-conjugates have been reported in the literature, attempting to reduce 
the systemic toxicity often encountered with single agents. In an effort to improve the 
delivery of Pt to cells, we have developed Pt-conjugates of expanded porphyrins (e.g., 
MGd) illustrated in Fig. 3.2, which are attractive due to their specific uptake into tumor 
cells.20,234 The texaphyrins are members of the “expanded porphyrin” class of 
macrocycles and have demonstrated coordination of larger metals. This has in turn 
allowed development of what appear to be several biologically well-tolerated 
experimental therapeutic agents.41 These MGd-Pt conjugates were designed to take 
advantage of the tumor specificity for Pt delivery; with the MGd moiety potentially also 
acting as a radiation sensitizer.147 
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Figure 3.2 Structure of the “MGd core,” MGd (a), amino-Pt conjugate (b), and aspartate 
conjugate (c). 
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We have previously described the synthesis of MGd-Pt conjugates (Fig. 3.2) 
utilizing a PEG spacer for solubility and piperidine (b), or aminosuccinate(c) for Pt 
coordination. In conjugate (b), attachment was effected via piperazine. From previous 
SAR studies of several N-side conjugates, possible spatial limitations for the interaction 
of the Pt(II) centers with DNA were proposed to account for the low activity observed. In 
the case of the aminosuccinate species (c), the poor performance could be ascribed to 
possible premature Pt release. Unfortunately, these MGd-Pt systems demonstrated poor 
solubility and low activity when subject to in vitro biological testing. Here we report the 
synthesis of a new MGd-Malonate-Pt analog, 3.1. The cytotoxicity of this analog was 
compared to carboplatin. In Appendix A we also report the  development of an 
experimental general synthetic strategy to simplify the preparation of additional 
analogues.  
 
3.2 SYNTHESIS OF  MGD-PLATINUM CONJUGATE 
Reviewing the historical success of the Pt malonates,179 235,236 and the PEG 
solubilized malonato-Pt conjugates recently prepared73,155,237 inspired us to work along 
similar lines. We started from solubilized acid 3.2, previously reported by this group to 
prepare MGd-Pt conjugates.147 The aminopropylmalonate-di-t-butyl ester 3.3, was 
prepared via the published procedure.155 Coupling was effected by activation  of the 
solubilized acid 3.2, mediated by DCC, followed by the addition of aminomalonate 3.3 to 
give amide 3.4a.   
The deprotection of the malonate diester was performed at the dinitro stage.  
Removal of the t-butyl groups, generally considered to be facile, could not be effected by 
treatment with neat TFA, formic acid, or TMS-triflate.238,239 Ultimately, 90/10 TFA/H2O, 
utilized in peptide deprotection, proved successful.240  The free acid 3.4b was then 
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subject to catalytic reduction, cyclization with dialdehyde 1.5b, and oxidative metallation 
with Gd(OAc)3, to give the MGd malonate 3.5a as the dominant product, with less than 
20% of the mono-decarboxylation product being observed. 
 
With the MGd malonate in hand we proceeded to the platination. Initial attempts  
to platinate MGd-malonate 3.5a with Pt “diaquo” 3.6 proved unsuccessful. Literature 
reports of the reaction of Pt-diaquo with acetate prompted us to exchange the MGd 
acetate anion for nitrate by loading on a tC-18 Sep-Pak column and eluting with NaNO3 
buffer to remove the NH4OAc buffer used in the initial purification. Here the goal was to 
remove both ammonia and acetate, species that readily coordinate to platinum.188 
A methanol solution of the resulting texaphyrin (nitrate) complex 3.5b was mixed 
with an aqueous solution containing one equivalent of diaquo Pt and left to stir for 24 
hours. Quenching the reaction by pouring into water gave a green solid, 3.1.  Analysis by 
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Scheme 3.1 Synthesis of MGd-propylmalonate Pt conjugate 3.1. 
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UV spectroscopy and LCMS provided support for a species that was consistent with the 
platinated-MGd product. By HPLC analysis the platinated MGd product eluted faster 
than the MGd-diacid.  As anticipated, aqueous solutions of the conjugate appeared to 
release Pt over time, as supported by HPLC analysis. The HPLC of aqueous solutions of 
the platinated-MGd demonstrated decreasing levels of the platinated material and 
increasing levels of the MGd-diacid 3.5b. This proved to be a reversible process, 
meaning the original HPLC trace corresponding to 3.1 could be regenerated by the 
addition of an excess of the Pt-diaquo complex.  The conjugate was stable in both high 
concentrations of nitrate (0.5-1.0 M, aq.) and in methanol solution. Purification was 
effected on reverse phase tC-18 with Methanol/KNO3 buffer. Desalting on the reverse 
phase tC-18 column by washing the bound material with water prior to elution with 
methanol gave the product which was evaluated for hydrolytic stability and tested against 
A549 cells.  
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Figure 3.4 Hydrolysis Study of MGd-Pt conjugate 3.1 in methanol and phosphate 
buffered saline (PBS). Methanol (3.1 □), PBS (3.1 ■). Hydrolysis rate (loss of % intact) is 
inferred from HPLC analysis.  
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3.6 AQUEOUS STABILITY STUDY OF MGD-PT CONJUGATES  
 
During purification of MGd-Pt conjugate 3.1, the conjugate demonstrated 
reversible loss of Pt-diaquo. Presumably this loss was through hydrolysis. The loss was 
found to be reversible by the addition of Pt-diaquo. The half life of platinum loss for the 
conjugate in water was estimated at ca. 48 h, similar to the carboplatin hydrolysis rate.  
In HPLC studies, the hydrolytic profile of conjugate 3.1 demonstrated t1/2 = 3 days 
(additional, tertiary malonate model conjugates: noted in appendix A containing a PEG2 
linker, and a propyl linker conjugate were also prepared and both demonstrated an 
aqueous hydrolysis profile with t1/2 = 9 days, the PEG conjugate Pt loss was confirmed as 
reversible on the addition of Pt-diaquo) The hydrolytic profile of conjugate 3.1 was 
reversible.Stirring the hydrolysis solution of 3.1 for one day at room temperature with 
excess “diaquo-Pt” resulted in regeneration of the peak at the original retention time for 
conjugate 3.1, with a corresponding decrease in the peak seen to increase during the 
 
Figure 3.5 Cell studies with A549 Cells and Carboplatin, MGd and MGd-Pt conjugate 3.1. 
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hydrolysis study.  
Toxicity testing (Fig. 3.5) in A549 cells by MTT assay demonstrated efficacy 
equivalent to non-targeting carboplatin.   
 
3.7 CONCLUSION 
 
In an effort to exploit the tumor localizing ability of MGd a Pt conjugate 
containing a malonate coordinating moiety was synthesized.  This compound 
demonstrated a hydrolysis rate similar to that of carboplatin. This conjugate also 
demonstrated efficacy against the A549 lung cancer cell line, similar to Carboplatin. 
Thus, we have confirmed our hypothesis that a MGd-Pt conjugate utilizing a malonate 
coordinating moiety demonstrate improved activity over the previous Gd-texaphyrin 
platinum conjugates. 
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3.8 EXPERIMENTAL METHODS  
General Procedures  
Unless otherwise noted, all reagents were obtained from commercial suppliers 
and used without further purification. Solvents were dried over molecular sieves except 
dichloromethane which was dried over CaH2.Toluene and methanol used in sp3-
texaphyrin syntheses was degassed by purging with argon for 5 minutes. Toluene and 
methanol used in the sp2-texaphyrin syntheses (MGd cyclization and metallation) were 
oxygenated by purging with air for 5-10 minutes, with additional purging being carried 
out during the reaction period for large scale preparations. The diacid 3.2 was prepared as 
previously repoprted.147 The intermediate 1.5b (2,5-bis[(5-formyl-3-hydroxypropyl-4-
methylpyrrol-2-yl) methyl]-3,4-diethylpyrrole) was supplied by Pharmacyclics, Inc. 
Inorganic reagent Gd(OAc)3.xH2O,was supplied by Strem Chemical Company. The 
(NH3)2PtI2 (DIP) used was kindly supplied by Johnson Matthey Biomedical Materials. 
Chromatography Merck type 60 (230-400 mesh) silica gel was used for column 
chromatography.  For small-scale work-up Sep-Pak cartridges were purchased from 
Waters or Fisher in 0.5-20 gram sizes of C-18, alumina or silica. TLC was carried out 
using the conditions noted below using Whatman K6F aluminum backed silica gel plates, 
unless otherwise noted. Alternatively glass backed C-18 plates were used.  
HPLC HPLC analyses were performed on a Beckman System Gold or Shimadzu 
Analytical/Preparative HPLC system equipped with PDA detector and a Zorbax XDB 5 
μM 5 x 100 mm column. An ammonium acetate buffer (30 mM, pH = 4.3) / acetonitrile 
(ACN) gradient (30-99% ACN over 20 minutes) was used for the analysis of the non-Pt 
MGd compoounds. A 0.1% TFA / ACN gradient (10-99% over 15 minutes unless 
otherwise noted) was used for analysis of the MGd platinum conjugates. The MGd-Pt 
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conjugate HPLC analysis was performed on the C18 column with 0.1% TFA and 
acetonitrile as the eluent and detection at 472 nm.  
NMR All 1H, and 13C NMR spectra were measured with a Varian Mercury 400 
(400 MHz.) or Varian Inova 500 (500 MHz.) spectrometer in CDCl3, D2O, CD3OD or 
D7-dmf. The NMR chemical shifts are reported in ppm relative to the solvent. Low 
resolution and high resolution electrospray mass spectrometry (ESI MS) were performed 
with a Thermo Finnigan LTQ  and Qq-FTICR (7 Telsa) instruments, respectively. Mass 
spectrometry (LRMS, HRMS) was carried out by the University of Texas at Austin Mass 
Spectrometry Facility. Elemental analyses were performed by Midwest Microlabs Inc. 
Electronic spectra were recorded on a Beckman DU-7 spectrometer.  
 
General Methods: Chromatography: TLC, Flash, SPE and HPLC  
 
TLC - Silica gel TLC of organic soluble samples commonly used EtOAc/hexanes or 
DCM as the eluents. The water solubilized PEGylated intermediates were 
chromatographed using 9:1 DCM:MeOH with HOAc or NH3 to further deactivate the 
silica gel unless otherwise indicated. Silica gel chromatography of the texaphyrins 
required 9:1:0.1 DCM:MeOH:HOAc as the eluent.  
Flash Chromatography - For the MGd complexes chromatography was typically 
performed by loading up to 1000mg MGd as a DCM solution on 75 cc pre-packed silica 
gel (1" diameter column) and eluting with 200-400 ml DCM, followed by 200-400 ml 
DCM/0.1-0.2% HOAc containing 5% MeOH, followed by the same solution at 10-40% 
MeOH.  This elutes the first small red and pale green impurities.  The main fraction is 
eluted with 400-800 ml DCM/HOAc solution containing 15% MeOH.  Relevant fractions 
are collected as 100-200 ml aliquots.  Relevant fractions can be re-chromatographed on 
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100 cc silica gel by diluting to 5% MeOH and loading directly onto the column.  Elution 
with DCM/0.1% HOAc at 10% MeOH removes the trace red and green impurities and 
the main product fractions are removed at a gradient of 15-40% MeOH in DCM/HOAc 
with 400-600 ml solvent.  
SPE - The MGd conjugates could also be purified on RP-tC18 SPE (Waters Sep-Pak) 
columns using gradients of MeOH or ACN against aqueous buffer (33mM NH4OAc for 
esters and fluorophores, 10-100 mM KNO3 or 0.1% TFA for other compounds), using 
NH4OAc or KNO3 buffers and acetonitrile or MeOH as the organic phase.  
Pt-diaquo complex preparation: 200  (NH3)2Pt(H2O)2+2(NO3)2- A solution of 
(NH3)2PtI2 (0.42 g, 1 equiv.) and AgNO3 (0.28 g, 2 equiv.) was dissolved in water (c.a. 
10 ml) and stirred overnight in the dark.  The solution was then centrifuged to pellet the 
silver iodide. The clear supernatant was removed and diluted as necessary. 
 
Experimental 
Synthesis of 2-(3-Amino-propyl)-malonic acid di-tert-butyl ester. 3.3155 To a 
solution of 3-phthalimidopropyl-di-t-butylmalonate (6.06 g, 15 mMol) in EtOH (75 ml) 
was added hydrazine (1.4 ml, 50% aq.). The solution  was held at 70 oC for 3 hours. On 
cooling to ambient temperature and stirring overnight a flocculent white precipitate had 
formed.  The EtOH was evaporated and the residue dissolved in DCM (2 x 100 ml). 
Washing with NaOH (250 ml, 0.5 N), drying with MgSO4 and evaporation gave an oil 
(3.74 g, 91%) The oil can be further purified by flash chromatography over silica gel 
(EtOAc, MeOH gradient 0-12%). TLC: EtOAc: MeOH 8:1 Rf = 0.6 (detection with 
EtOH solution of 0.1% ninhydrin, 1% decylaldehyde). 1H NMR(CDCl3 300 MHz) δ1.42 
(m, ~18 H), 1.52 (bs, 2H), 1.83 (q, 2 H), 2.72, (t, 2H) 3.12 (s, 1H). MS (CI) (M+H)+ 274.         
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Synthesis of 2-[2-(2-{2-[2-(2-Methoxy-ethoxy)-ethoxy]-ethoxy}-4,5-dinitro-
phenoxy)-acetylamino]-malonic acid di-t-butyl ester. 3.4  To a solution of acid 3.2 
(5.61 g, 14 mMol) in DCM (200 ml) with NHS (1.65 g, 14 mMol) was added DCC (3.6 
g, 1.2 equiv.). The resulting solution was stirred briefly before the addition of the amine 
3.3  (3.74 g, 13.7 mMol) and the resulting solution was left to stir overnight. The solution 
was then filtered and evaporated. The product was purified by flash chromatography over 
silica gel (EtOAc:hexanes 1:1) to provide the product, an unstable oil which undergoes 
decomposition under chromatography conditions(3.24 g, 36 %). HPLC (329nm): Tr 14.87 
min, 91.24%. TLC( 9:1 DCM: MeOH): Rf = 0.2. MS (EI) (M+H)+ 660. HRMS(EI) 
calculated for C29H46N3O14 660.2980, found 660.2978. 1H NMR(400 MHz, CDCl3) δ 
1.45 (s, 18 H), 1.60 (m, 2H), 1.81 (m, 2 H), 3.13 (t, J=7.2 Hz, 1 H), 3.36 (m, 5 H), 3.53 
(m, 2 H), 3.53 (m, 2 H), 3.61-3.67 (m, 4 H), 3.72 (m, 2 H), 3.93 (m, 2 H), 4.37 (m, 2 H), 
4.62 (s, 2 H), 7.00 (broad t, 1 H), 7.52 (s, 1 H), 7.52 (s, 1 H). 13C NMR(100 MHz, 
CDCl3) δ 25.6, 26.9, 2707, 38.6, 53.2, 58.8, 68.8, 69.2, 69.7, 70.3, 70.4, 70.7, 81.4, 109.2, 
110.2, 136.0, 137.8, 149.4, 151.9, 166.2, 168.5. Anal. Calcd for C29H45N3O14: C 52.80%; 
H 6.88%; N 6.37%. Found C 46.13%; H 5.96%; N 5.32%. 
Synthesis of MGd-malonate 3.5a The di-t-butyl protected dinitro malonate 3.4, 
1.69 g. (2.56 mMol) was stirred for 1 h. in 15 ml 90% TFA, 10% H2O which cleanly 
deprotected the malonate (90+% by tlc and NMR) to give the diacid. The resulting 
solution was evaporated, then evaporated with 50 ml chloroform. The residue in 
MeOH(50 ml) was hydrogenated using Pd/C (0.42 g, 10% wet) catalyst at 40 psi for 18 
hours. The solution was filtered through Celite and added to 1.28 g (2.66 mMol) 1.5b in 
50 ml MeOH and HCl (0.5 ml, 3N). The solution was held at 50 oC for 3 h. Complete by 
tlc, the solution was evaporated. Metallation: The residue was dissolved in MeOH (100 
ml) with 1.10 g. Gd(OAc)3 (1.05 equiv.) and 4 ml Et3N. The solution was held at 50 oC 
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for 2 hours, complete by tlc. The solution was  quenched with HOAc (4 ml) and 
evaporated. The residue was dissolved into 10 ml buffer (NH4Oac, 33 mM, pH 4.3) and 
loaded onto a t-C-18 SPE cartridge (10 g). Elution with 80:20 ACN:buffer gave the 
product. This solution was diluted with buffer, again loaded onto the column, washed 
with water and eluted with MeOH. Evaporation and titration with Et2O gave the product 
(0.18 g, 6.2 %) 
HPLC (472nm): Tr 4.28 min 96.24%. MS (EI) (M – 2 OAc)+ 1084. HRMS(EI) 
calculated for C49H62GdN6O12 1084.3667, found 1084.4425. Anal. Calcd for 
C51H65GdN6O14: C 53.57%; H 5.73%; N 7.35%. Found C 53.07%; H 5.73%; N 7.55%. 
Synthesis of MGd-Pt 3.1. Starting from 3.5a (230 mg, mMol) was dissolved in 
MeOH (10 ml) and diluted with KNO3 (40 ml, 100 mM) and loaded on a C-18 SPE 
cartridge (10 g). The 3.5b (NO3) was eluted off with MeOH (15 ml). The MeOH solution 
was mixed with (NH3)2Pt(H2O)2+ (2 equiv.) and allowed to react in the dark for 48 hours. 
The resulting solution was diluted with an equal volume of KNO3 (40 mM) and loaded 
on a C-18 SPE cartridge (10 g).  Elution with KNO3 (40 mM)/MeOH: 60/40 removed 
impurities. The product was eluted from the SPE cartridge with KNO3 (40 mM)/MeOH: 
40/60. The product was desalted by dilution 1:1 with KNO3 (40 mM), reapplying to the 
SPE cartridge was followed by washing with HNO3 (10mM) and eluting with MeOH 
containing 5% HNO3 (10mM). The product was precipitated by the addition of Et2O and 
centrifugation to give the green solid (84 mg, 9%). 
HPLC (470 nm): Tr  7.36 min  95.97%. MS (EI) (M – NO3)+ 1374. HRMS(EI) 
calculated for C49H66GdN9O15GdPt: 1373.3567; found: 1373.3574.  UV: 419 (sh) 4.98e4, 
474 1.19e5, 742 3.43e4. Anal. Calcd for C49H67GdN10O18GdPt: C 40.97%; H 4.70%; N 
9.75%. Found C 40.67%; H 4.81%; N 9.46%.  
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Cytotoxicity Measurements in A549 Lung Cancer Cells 
The human lung carcinoma cell line A-549 was obtained from ATCC and 
cultured in DMEM supplemented with 10% FBS and streptomycin/penicillin mixture. 
Cell lines were maintained as monolayer cultures in plastic culture flasks grown at 37oC 
in a humidified atmosphere of 5% CO2/95% air. The cytotoxic activity was measured by 
MTT assay. A 96-well plate was dispensed with 50 ul of cell suspension (4 x 103 
cells/well). After the cells had settled (24 hours), the test compounds at equivalent 
concentrations (UV470 basis for MGd and the MGd-conjugate) were dissolved in media 
and sterilized by gamma irradiation, then 50 uL added. After incubation for 48 hours at 
37oC in 5% CO2 the media was removed and cells washed once with serum-free DMEM 
containing no indicator. The cells were then incubated for 2-4 hours with MTT (1 mg/ml) 
in serum-free media. The media was removed and the cells were lysed with 50 ul 
isopropanol. The UV absorbance was measured at 595 nm against untreated wells and the 
IC50 values were calculated. 
 
68 
 
Chapter 4: Quaternary Amine Platinum Therapeutic Agents 
4.1 INTRODUCTION 
 Cisplatin and carboplatin, are first and second generation therapeutic anticancer 
agents; however, they suffer from tumor resistance and non-specific toxicity. Third-
generation oxaliplatin is an approved Pt compound with more lipophilic N-side 
substitution, and several experimental lipophilic N-side Pt therapeutic agents have been 
subsequently developed (Figure 4.1d-i). Oxaliplatin demonstrates therapeutic activity in 
resistant tumors; however, it suffers from low water solubility and neurotoxicity, thus 
efforts continue to develop improved platinum analogues.180 We hypothesized that 
cationic, lipophilic N-side Pt therapeutic agents could retain the activity associated with 
lipophilicity, while the cationic charge, (analogous to Figure 4.1 g-i) appears to assist in 
efficacy. 
Extensive structure activity relationship (SAR) studies of Pt compounds have 
shown that the highest activity is obtained with platinum is coordinated with alkylamines 
such as 1,2-diaminocyclohexane (DACH), small alkylamines, or o-phenylene 
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Figure 4.1. Platinum therapeutic agents: (a) cisplatin, (b) carboplatin, (c) oxaliplatin, 
(d) JM-216, (e) heptaplatin, (f) terpene-pyridine analog, (g - i) aminopyridine analogs
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diamine.175,202-205 Generally these (alkylamine)2-Pt complexes exhibit low water 
solubility and so far modifications such as such as oxygenation,  intended to make these 
compounds more soluble, have typically led to lower efficacy, heptaplatin  being a 
notable exception.206,207 
The structures in Figure 4.1,197,199-201,241 containing small lipophilic N-side 
ligands, demonstrate in vitro activity. These finding are in agreement with structure 
activity relationship (SAR) studies, in which therapeutic activity has been correlated with 
small lipophilic ligands on Pt.242,202,204 The experimental pyridine family analogs (g - i) 
demonstrate activity against resistant tumors. These compounds, being more polar than 
oxaliplatin, may also have higher solubility and improved (or altered) uptake/retention 
profiles. These agents are also possibly cationic at cellular pH. Thus, the experimentally 
observed activity of the above pyridine-Pt compounds is in broad agreement with the 
lipophilicity and efficacy correlation proposed in SAR studies.  
The above Pt therapeutic agents are thought to act as agents that bind to DNA and 
damage DNA. Cellular resistance to Pt anti-cancer agents is thought to involve excretion 
of the active Pt agent out of the cell, perhaps complexed to glutathione or other cellular 
molecules.243,244 Thus, cellular retention of Pt therapeutic agents is an important 
consideration in the design of these compounds.  
As noted previously, key objectives of the present study were to i) investigate the 
toxicity of lipophilic-cationic compounds and their lipophilic-cationic-Pt derivitives in 
cancer cells, ii) develop and utilize synthetic and testing methodologies that allow rapid 
synthesis and screening of lead candidates, and,  iii) develop lead Pt compounds from 
these initial studies. In this context, we were inspired specifically by  delocalized 
lipophilic cations (DLC), species which demonstrate cellular uptake and retention. 
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From numerous imaging studies it is clear that lipophilic cations can either embed 
in the membrane such as is the case for voltage sensitive dyes (e.g. NK-529208), or they 
can be transported through cellular membranes and accumulate in organelle such as 
mitochondria that have a negative membrane potential.115 Delocalized lipophilic cations 
(DLC) are known to act as transport agents or toxins and have been proposed for 
therapeutic use. Therapeutically significant, the mitochondria localizing rhodamine also 
has demonstated activity in multiple drug resistant (MDR) tumors.217 Separately, 
triphenylphosphonium cation demonstrates mitochondrial localization and has been 
proposed as a therapeutic agent carrier.209-211 Further support for the lipophilicity/ 
retention hypothesis is demonstrated by a combinatorial study of fluorescent styryl 
quaternary cations in which 53 of 119 compounds synthesized were observed localized in 
the nucleus or mitochondria by fluorescence microscopy.115    
Some lipophilic cations are also known to demonstrate significant cell toxicity, 
acting as detergents that damage cell membranes. Toxic cations include dequalinium 
chloride,212-214, C6-DAP,215 and cetylpyridinium,216 which are used as a herbacide,  
polymeric antibacterial agent, and topical disinfectant,  respectively. The above 
mentioned  lipophilic quaternary cationic compounds do not specifically target tumors 
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Figure 4.2. Cisplatin analogs: betaine 4.1, lipophilic diamine-PtCl2 4.2, 
precursors 4.4, 3,4-diaminopyridine-PtCl2, 4.3, and ligand precursor 4.5. 
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and appear to act as either highly toxic detergents, or are inert, thus they have not 
generally been used therapeutically. 
 
The experimental cationic betaine-Pt compound 4.1 218 (Figure 4.2) demonstrates 
improved efficacy over cisplatin in cell studies, presumably through DNA damage. We 
hypothesized that Pt therapeutic agents, with  robust attachment of DLCs could result in 
agents both soluble and efficacious. An interesting anomoly is demonstrated by the 
experimental lipophilic diamine Pt complexes 4.2 and 4.3.  These species have a 400-fold 
and 15-fold lower toxicity, respectively as the Pt complex, compared to the amine ligand 
precursors 4.4 and 4.5.245 246 While presumably such Pt agents would possess improved 
cellular retention, possibly overcoming resistance mechanisms such as export of the 
active Pt species, unfortunately, metallation has diminished their efficacy. From this 
background we set out to develop improved therapeutic agents. 
 
4.2 RESULTS  
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Scheme 4.1. Synthesis of  quaternary diaminopyridines and Pt complexes. 
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We hypothesized that quaternarization of 3,4-diaminopyridine  4.5, (Scheme 4.1) 
would  simultaneously inactivate the pyridine nitrogen against reactivity with Pt species, 
and improve the solubility of these 
compounds. The synthesis of the methyl and benzyl quaternary derivitives having been 
previously reported, reaction of pyridine 4.5 with alkyl halides under either room 
temperature or microwave assisted conditions, gave the N-quaternary compounds 4.6 - 
4.9. The high nucleophilicity of the pyridine nitrogen gave selective quaternization, 
producing a product with 1H NMR data consistent with only the desired isomer.247 
Although chromatography has been reported for these quaternary salts using highly polar 
conditions, the reaction selectivity allowed purification by recrystallization. These 
quaternary aminopyridine species are expected to be cationic at cellular pH. These 
aromatic cationic “diamine” compounds were thus designed to give non-labile 
coordination to Pt(II), a flat ring to fit the steric requirements for DNA intercalation, and 
we anticipated tuning the quaternary substitution to optimize properties. 
Figure 4.3  A549 cell viability by MTT assay 
following 96  h incubation with quaternary 
ligands (white bars) and their Pt complexes 
(black bars) at 20 μM. 
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Scheme 4.2  Quaternary Pt salt 4.11 
demonstrating highest cytotoxic activity  
and possible degradation product 4.12. 
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With the quaternary amines salts in hand, the in situ screening method of Ziegler 
was used (Scheme 4.1).200 Briefly, K2PtCl4 was activated in situ with excess iodide. In 
situ reaction with the amines generated the putative bis-coordinated Pt-complexes of type 
4.10. The solutions of the complexes were prepared with a 1:1 ratio of Pt to ligand. 
Addition of DMF dissolved the resulting complexes, and the excess halide was removed 
by reaction with AgNO3. Centrifugation, followed by addition of KCl and evaporation 
gave the complexes. 
 
4.3 CYTOTOXICITY STUDY  
 
The products solutions were evaluated for toxicity using a standard MTT assay 
(Figure 4.4). Both the ligands 4.6 – 4.8  and their putative Pt conjugates, after dissolving 
in minimal dimethylacetamide, were evaluated for toxicity in the A549 cell line (Fig. 4.3) 
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Figure 4.4 Evaluation of cytoxicity of cisplatin and 4.11 (PtQ) in the A549 lung 
cancer cell line by MTT assay.μM 
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at 20 μM concentration.248 The resulting solutions were also assayed for total Pt content 
by ICP-MS. The insolubility of the C18 salt 4.9 precluded biological testing. While this 
methodology allowed rapid screening, the toxicity of the ligands and AgNO3, as well as 
the detoxifying effect of Pt coordination needed to be accounted for. Loss of the Pt-
complexes during the halide precipitation was also of concern.  
Toxicity experiments with AgNO3 demonstrated no significant toxicity over 
controls. The Pt-L toxicity was evaluated on the basis of Pt content, to correct for ligand 
toxicity. The results obtained in this way (Fig. 4.3) confirmed that the benzyl Pt 
compound 4.11 was the most active in this series. This series broadly parallels 4.2 – 4.5, 
toxicity decreasing on metallation and toxicity increasing with lipophilicity across the 
series, until intersecting with 4.11. 
The synthesis of 4.11, was scaled up by reacting the quaternary pyridine salt 4.8 
in methanol directly with an aqueous solution of K2PtCl4. This reaction initially (1 h 
stirring) gave a flocculent pink precipitate. On standing 2-3 weeks in the dark, tan orange 
spherical crystals were produced that were unfortunately not suitable for X-ray 
diffraction studies. LC-MS and HRMS analyses for the orange crystals were consistent 
with structure 4.11. The aqueous solutions of this material slowly changed color from 
pale yellow to blue, assigned as being a structure incorporating water ligand on the Pt. 
Such an arrangement is in agreement with LCMS studies of fresh and aged solutions, 
which revealed the existence of two discreet compounds. In fresh solutions, 4.11 
exhibited Tr = 5.29 minutes, M+ =  465. Over time the LCMS  of the solution changed to 
a new product with Tr = 4.15 minutes, M+ = 500. The LCMS values agree with the 
assignment of the initial cationic orange compound 4.11 as the late eluting product, and 
the slowly formed blue compound as the early eluting product, as the higher molecular 
weight compound, proposed structure 4.12. This proposed structure incorporates an extra 
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chloride, as the benzyl ylide in agreement with the MS data. The proposed zwitterionic 
structure is in agreement with a product eluting more rapidly by HPLC, having less 
lipophilic character. The analogous simpler Pyridinium chlorophehylmethylylide has 
been previous reported, prepared by alternate means.249  Fresh solutions of 4.11, more 
stable in DMSO, less so in water, gave predominantly the longer retained M+ = 464 
LCMS peak, the M+ = 500 increasing over time. Toxicity studies of solid 4.11 in the 
A549 lung cancer line by MTT assay demonstrated efficacy comparable to cisplatin, with 
LD50 = 6 μM following 96 h exposure. 
4.4 CONCLUSION 
To study putative N-side lipophilic cations, a series of increasingly lipophilic 
catioins and their putative platinates were synthesized. As the ligands themselves 
demonstrated significant toxicity, efficacy screening of the in-situ synthesized conjugates 
for efficacy was based on Pt content to account for the ligand toxicity bias. The benzyl 
diamino-Pt compound was then specifically synthesized and characterized. It 
demonstrated efficacy equivalent to cisplatin against A549 cancer cells. This confirms 
our hypothesis that cationic lipophilic Pt compounds can retain therapeutic activity. 
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4.5 EXPERIMENTAL SECTION 
 
Materials. Unless otherwise noted, all reagents were obtained from commercial suppliers 
and used without further purification. Solvents were dried over molecular sieves. 
Inorganic K2PtCl4 was supplied by Aldrich and Strem Chemical Company.  
HPLC Analyses. HPLC analyses were performed on a Shimadzu Analytical/Preparative 
HPLC system equipped with a PDA detector. An ODS C18aq column (100 x  4.6 mm, 
YMC) using 0.1% TFA and MeOH gradient (10% - 95% organic) as eluent, a flow rate 
of 0.5 ml/min, with detection at the noted wavelength.  
NMR Spectroscopy. All 1H, 13C and 195Pt NMR spectra were measured with a Varian 
Mercury 400 (400 MHz.) or Varian Inova 500 (500 MHz.) spectrometer in CDCl3, D2O, 
CD3OD or D7-dmf. The NMR chemical shifts are reported in ppm relative to the solvent 
except in the case of 195Pt (relative to K2PtCl4 in D2O). Low resolution and high 
resolution electrospray mass spectrometry (ESI MS) were performed with a Thermo 
Finnigan LTQ  and Qq-FTICR (7 Telsa) instruments, respectively. Mass spectrometry 
(LRMS, HRMS) was carried out by the University of Texas at Austin Mass Spectrometry 
Facility.  
Elemental Analyses. Elemental analyses were performed by Midwest Microlabs Inc. 
Platinum analysis was performed by Thomas Kreschollek of the Holcombe Research 
Group at the University of Texas at Austin using ICP-MS and commercial Perkin-Elmer 
platinum standards. Samples for ICP-MS were dissolved in dilute nitric acid.  
Synthesis. The general procedures for preparing the intermediates and compounds are as 
follows. 
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Synthesis of the Quaternary pyridine ligands: The quaternary pyridine salt was 
prepared according to the published procedures.250 Briefly, the aminopyridine and the 
appropriate alkyl halide were stirred at room temperature for 24 h in acetonitrile. If no 
precipitate was visible, the solution was either heated to 70 oC for 2-12 hours, or placed 
in a in a microwave reactor at 70 oC for 2-60 minutes. The solid products were isolated 
by filtration. All products were analyzed by NMR spectroscopy and demonstrated 
features in agreement with a single product, in agreement with previous sysnthesis of the 
methyl and benzyl derivitives. 
Synthesis of the Pt-diaquo: The (NH3)2Pt(H2O)2+2(NO3)2- was prepared 
according to published procedures. 179 Briefly  (NH3)2PtI2 (0.42 g, 1 equiv.) and AgNO3 
(0.28 g, 2 equiv.) was dissolved in water (c.a. 10 ml) and stired overnight in the dark.  
The precipitated solid removed by contrifugation and the clear supernatant was removed 
and diluted.  
Synthesis of the Quaternary pyridine-diaminoplatinum dihalide (in situ 
preparation): The amine ligand was metallated according to the high throughput 
procedure of Ziegler.200 Briefly, K2PtCl4 (200 mM, 50 μL) was activated by the addition 
of KI (800 mM, 50 μL) and was mixed in equimolar quantities with a methanolic 
solution of the amine quaternary salt (200 mM, 150 μL ), and held for 1-4 h at 37 oC. The 
resulting solution was then treated with AgNO3 (200 mM, 500 μL)and methanol (500 
μL) and the precipitate removed by centrifugation. The supernatant was removed, treated 
with dilute HCl and again centrifuged. Methanol was added to redissolve precipitated 
product. The resulting solutions were evaporated, folowed by dilution with minimal 
dimethylacetamide, followed by toxicity evaluation (20 μM concentration) by cell assay. 
The same dimethylacetamide solution was assayed for Pt content by ICP-MS. 
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Synthesis of the Pyridinium, 3,4-diamino-1-methyl-iodide. 4.6251 To a solution 
of the amine (0.5 g, 4.6 mMol) in acetonitrile (4 ml) was added MeI (0.7 g, 4.9 mMol). 
The solution was   left to stir overnight. Filtration and washing with acetone gave the 
product as a white solid (0.66 g, 57%). HPLC(298nm): Tr  3.44 min, 99.71 %. 1H 
NMR(400 MHz, d6- DMSO ) δ 3.84 (3H, s), 5.50 (2H, bs), 6.68 (1H, d, J = 6.8 Hz), 7.28 
(2H, bs), 7.50 (1H, d J = 1.7 Hz), 7.70 (1H, dd J = 6.8, 1.7 Hz). 13C NMR(100 MHz, 
CDCl3) δ 45.5, 107.4, 125.7, 132.9, 135.5, 147.7. MS (EI) (M-I)+ 124.  
Synthesis of the Pyridinium, 3,4-diamino-14-{2-[2-(2-Methoxy-ethoxy)-
ethoxy]-ethyl}-benzene-1,2-diamine. 4.7 To a solution of the amine (0.5 g, 4.6 mMol) 
in ACN (4 ml) was added MeOPEG3OTs (1.6 g, 5.0 mMol). The solution was   heated in 
a microwave reactor (80 oC, 15 min). Cooling, filtration and washing with acetone gave 
the product as a tan solid (1.82 g, 71%). HPLC (302nm): Tr  5.58 min, 90.30 %. 1H 
NMR(400 MHz, d6- DMSO ) δ 2.27 (3H, s), 3.20 (3H, s), 3.37(2H, m) 3.43 (4H, m), 3.49 
(2H, m), 3.70 (2H, t J = 4.8 Hz), 4.23 (2H, t J = 5.1 Hz), 5.49 (2H, bs), 6.69 (1H, d, J = 
6.5 Hz), 7.01 (2H, d J = 8.5 Hz), 7.35 (2H, bs), 7.45 (2H, d J = 7.9 Hz), 7.58 (1H, s), 7.74 
(1 H, dd J = 6.8, 1.4 Hz). 13C NMR(100 MHz, d6 – DMSO) δ 26.2, 62.6, 63.5, 74.5, 75.0, 
75.2, 76.7, 130.9, 133.5, 137.5, 143.2, 151.0, 153.0. MS (EI) (M-OTs)+ 256. HRMS(EI) 
calculated for C12H22N3O3 256.1656, found 256.1659. Anal. Calcd for C19H29N3O6S: C 
53.38%; H 6.84%; N 9.83%. Found C 53.46%; H 6.65%; N 10.07%.  
Synthesis of the Pyridinium, 3,4-diamino-1-(phenylmethyl)-chloride. 4.8250. 
To a solution of the amine (1.1 g, 8.7 mMol) in MeOH (15 ml) was added BzCl (0.99 g, 
9.0 mMol). The solution was left to stir for three days. The solution was added to EtOAc 
(200 ml) and the product initially oiled, then crystallized. The solid was isolated by 
centrifugation and washed with acetone to give a white solid (1.02 g, 48%). HPLC (308 
nm): Tr  12.36 min, 96.97%. 1H NMR(400 MHz, d6- DMSO ) δ 5.31 (2H, s), 5.68(bs 
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NH2), 6.78 (1H, d, J = 6.8 Hz), 7.31-7.44 (5H, m), 7.59 (1H, d J = 1.7 Hz), 7.94 (1H, dd J 
= 6.5, 1.7 Hz). 13C NMR(100 MHz, CDCl3) δ 60.8, 107.4, 123.7, 128.7, 129.3, 129.7, 
133.5, 134.8, 136.4, 148.4. MS (EI) (M-Cl)+ 200. HRMS(EI) calculated for C12H14N3 
200.1189, found 200.1188.  
Synthesis of the Pyridinium, 3,4-diamino-1-octadecyl-bromide. 4.9  This 
compound was prepared according to the general procedure above. To a solution of the 
amine (0.62 g, 5.7 mMol) in ACN (2 ml) was added octadecyl bromide(1.93 ml, 5.7 
mMol). The solution  was heated in a micorwave reactor (120 oC, 40 minutes). Filtration 
and washing with acetone gave the product as a white solid (0.97 g, 39%). HPLC (304 
nm): Tr  17.96 min, 95.67%. 1H NMR(400 MHz, d6- DMSO/D2O/MeOH ) δ 0.83 (3H, t J 
= 7.1 Hz), 1.21 (30, bs), 1.69 (2H, t J = 6.9 Hz), 4.05 (2H, d J = 7.2 Hz), 5.50 (2H, bs), 
6.69 (1H, d J = 6.7 Hz), 7.35 (2H, bs), 7.59 (1H, s), 7.77 (1H, d J = 6.7 Hz). 13C 
NMR(100 MHz, d6- DMSO ) δ 14.6, 21.5, 22.8, 29.4, 29.6, 29.7, 29.9, 32.0, 58.14, 107.5, 
124.2, 133.1, 134.7, 148.0. MS (EI) (M-Br)+ 363. UV: λ = 232, 304 Anal. Calcd for 
C23H44BrN3: C 62.43%; H 10.02%; N 9.50%. Found C 62.51%; H 10.22%; N 9.50% 
Synthesis of the putative Platinum-Amine complexes (in situ). The reaction 
was carried out as noted above. The products were complex mixtures by HPLC analysis. 
The dried samples were dissolved in dimethylacetamide and diluted with PBS for 
biological testing. Samples were assayed for Pt by ICP-MS. Low resolution ESI analysis 
of the L-Pt complexes gave results in agreement with predictions for the Pyridinium-Pt 
complexes with loss of ligand anion (methyl (M+ calculated 389, observed 388), PEG3 
(M- = 555), and benzyl (M+H = 466)). 
Synthesis of the [1-(phenylmethyl)-3,4-diaminopyridinium chloride] 
dichloroplatinum. 4.11 (Preparative Scale) A solution of K2PtCl4 (0.44g mMol, 
200mM) in water was added to a solution of diaminopyridine (0.27g, 200 mM) in 
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methanol. A volume of methanol equal to that of the pyridine solution was then added 
and the resulting solution allowed to stand in the dark for 2 weeks. The initially white-
pink precipitate turned to orange spherical crystals under a flocculent blue-green 
precipitate. The fluffy blue green precipitate was removed by decantation and tituration 
of the orange solid with the mother liquor. The resulting orange solid was isolated by 
filtration and washed with methaol to give 4.11 (0.247g, 49%). HPLC (278nm): Tr 6.88 
min, 97.12% LCMS ESI: Tr(M): 5.30 min (464.16). LCMS (EI) (M-H)+ 464, (M+ Cl)+ 
500. HRMS(EI) calculated for C12H14N3Cl2194Pt: 464.0192; found: 464.0194. HRMS(EI) 
calculated for C12H14N3Cl3194Pt: 499.9901; found: 499.9906. 1H NMR(400 MHz, d7- 
DMF ) δ 3.67 (s, 2H), 5.78 (s, 2H), 7.38 (d, 1H), 7.58-7.65 (m, 7H), 8.19 (s, 4H), 8.51 (d, 
1H, J = 1.7 Hz),8.60 (p, 2H, J = 7.2, 1.7 Hz). 13C NMR (100 MHz, d7- DMF ) δ 61.0, 
111.0, 126.3, 128.1, 129.1, 129.4, 135.7, 136.6, 140.3, 153.5. 195Pt NMR(86 MHz, d7- 
DMF ) δ (K2PtCl4 standard, 110 mg/ml in D2O) 2887 ppm (small 3327 ppm peak). 195Pt 
NMR(86 MHz, d7- DMF ) 4.11 (15 mg/ml d7-DMF 2613 ppm. UV: λmax = 278. Other 
hplc studies: Solid 4.11, Tr = 5.30 min, 92% assay converts to: 4.12, blue solution, on 
standing Tr = 3.97 min 82%. Anal. Calcd for C12H14N3Cl3Pt: C 28.73%; H 2.81%; N 
8.38%. Found C 28.41%; H 2.84%; N 8.14. CH correlation by NMR: (C ppm/H ppm): 
61.4/5.6; 111.4/7.3; 126.6, 129.0, 129.5, 129.7/~7.5; 136, 137/8.3; 140.6/8.4; 153.8/no H 
 
Cytotoxicity Measurements in A549 Lung Cancer Cells 
The human lung carcinoma cell line A-549 was obtained from ATCC and 
cultured in DMEM supplemented with 10% FBS and streptomycin/penicillin mixture. 
Cell lines were maintained as monolayer cultures in plastic culture flasks grown at 37oC 
in a humidified atmosphere of 5% CO2/95% air. The cytotoxic activity was measured by 
MTT assay. A 96-well plate was dispensed with 50 ul of cell suspension (4 x 103 
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cells/well). After the cells had settled (24 hours), the test compounds at equivalent 
concentrations were dissolved in DMSO and sterile filtered, then 5 uL added. After 
incubation for 48 hours at 37oC in 5% CO2 the media was removed and cells washed 
once with serum-free DMEM containing no indicator. The cells were then incubated for 
2-4 hours with MTT (1 mg/ml) in serum-free media. The media was removed and the 
cells were lysed with 50 ul isopropanol. The UV absorbance was measured at 595 nm 
against untreated wells and the IC50 values were calculated. 
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Figure 5.1 MGd BODIPY 5.2 and porphyrin 5.3 conjugates  
 
Chapter 5:  Conclusion and Future Directions 
 
 
In preliminiary studies the lipophilic and fluorescent conjugates were developed 
attempting to understand localization and efficacy correlations. At the cellular level, in 
these studies MGd and its analogues were observed to distribute diferentially. We viewed 
these efforts as an early step in the development of more useful conjugates.    
In the course of the fluorescent studies, the MGd-Rho conjugate was observed to 
localized in the mitochondria of A549 cells, the MGd-FITC conjugate localized in the 
nucleus. The A549 cell line in toxicity studies with ascorbate adjuvant, as compared to 
the ascorbate sensitive Jurkatt leukemia cell line, demonstrated significantly lower 
sensitivity to MGd and it’s fluorescent conjugates. The A549 cell line as compared to the 
ascorbate sensitive Jurkatt cell line, required 20-fold higher ascorbate levels and X-ray 
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irradiation before significant toxicity was observed.129 In both cases however, apparent 
synergy was observed. 
The conjugation of MGd to fluorophores with higher quantum yield hasboth 
technically simplified the imaging process of “MGd” as lower concentrations are more 
easily observed, and has demonstrated that these fluorescent conjugates have a different 
sub-cellular distributon. A reasonable extension of this work (Fig. 5.1) is to develop 
additional MGd fluorescent conjugates containing BODIPY 5.2 and porphyrin 5.3 
moieties, based on a pyrrole motif. These can be envisioned as arising from published 
dinitro-BODIPY derivative 5.4, and dinitroporphyrin 5.5 (the mononitro derivative 
having been reported), respectively. The resultant MGd-conjugates 5.1 and 5.2 are 
expected to be fluorescent. Preliminary experiments utilizing the aforementioned 
synthetic intermediates have provided samples with spectral and LCMS properties in 
agreement with those expected for the above structures 5.2 and 5.3. An additional reason 
to synthesize these compounds is that they may also possess redox properties differing 
from the MGd compounds prepared to date. Altering the redox properties of MGd has 
been another ongoing project within the Sessler group, in an effort to improve the 
therapeutic efficacy of MGd.  
Separately, continuation of the MGd-Pt conjugate synthetic efforts reported here 
have resulted in the preparation of two new conjugates, with spectral data in agreement 
with A1 (see Appendix A) as well as a simpler, anologous “propyl” linked conjugate 
which demonstrated solubility issues. Attempting to utilize the biolocalization of MGd, 
the first water soluble MGd-platinum conjugate 3.1  synthesized in the course of this 
study demonstrated equivalent toxicity to carboplatin.  This PEG solubilized conjugate 
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Figure 5.2 Proposed MGd-M conjugates (5.6-5.9) and precursors (5.6a-c). 
did not suffer from the low solubilility issues of previous MGd-Pt conjugates. The other 
conjugates, model compound in Appendix A, while less soluble, were proof in principle 
of a route that appears to enable both rapid synthesis and wide structural variation. 
Additionally gratifying was the preliminary aqueous stability study of conjugate A1, 
which demonstrated by HPLC the conjugate decreasing over time, reversing on the 
addition of Pt-diaquo. The HPLC traces of the study in Appendix A indicated more 
rapidly dissappearance for the tertiary malonate conjugate 3.1 than for the quaternary 
conjugate A1. 
 
Modification of proposed model compound A1 into a useful therapeutic agent 
such as the proposed 5.6 can be envisioned as arising from analogs with a solubilizing 
PEG chain, synthesized via known routes.252,253  Further improvements in efficacy may 
be attainable by the coordiation of therapeutic Pt moieties with demonstrated therapeutic 
activity, which can be envisioned as arising from dihalides such as 5.6a (oxaliplatin 
precursor), 5.6b (JM-216 precursor), and 5.6c (ZD0473 precursor). 
85 
Thus, based upon the preliminary MGd-Pt results, a series of tri-PEG-linked MGd 
conjugates 5.6 and carboxylato-chelators 5.7, appears synthetically justified.  The readily 
derivitized tricarboxymethane254 derivatives were of  interest due to both their tri-
coordinate nature, and the ability to readily convert them to conjugates in the ester state, 
then hydrolysis gives a coordinating species. A possible addional feature is that, on 
exposure to acidic conditions, the loss of a carboxylate renders the remaining malonate 
fragment a poorer coordinating species; thus it could be envisioned that under acidic 
cellular conditions, loss of carboxylate would render the Pt-Malonate more susceptible to 
hydrolysis, leading to greater release of Pt for chemotherapeutic activity. 
A potentially fruitful area as well also involves studying in greater detail the 
relationship between the stability of the oxo-side tricoordinate MGd-Pt compounds 5.7 
and in vitro efficacy. Such additional model studies with HPLC evaluation of hydrolysis 
rates may help uncover a substituent/hydrolysis rate correlation. To the extent this proves 
true, it would allowing the rates of hydrolysis of the putative new conjugates to be 
tailored for use with a given tumor or cell types.  
Additionally, along these lines, increasing steric hindrance holds potential for Pt 
conjugates, worth investigating. While these tricoordinate compound  presumably are 
more stable, possibly also worthwhile is effecting increased steric hindrance via linkers 
such as the 2,2-diethyl-1,3-dibromopropane spacer segment, as well as increasing 
malonate quaternary substitution.255  
The MGd malonate chemistry developed to date has been for Pt conjugates. 
Vanadium conjugates may also hold significant promise as Cp2V(AcAc) was recently 
reported to suppress angiogenesis. As Cp2V+2 coordinates readily to AcAc, MGd-V 
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conjugate 5.8 can be envisioned. The AcAc moiety, a conjugation system which 
theoretically does not interfere with the Pt-Malonate chemistry, this possibly could be 
elaborated to dual metal releasing agents, containing both Pt(NH2R)2 and Cp2V 5.9.  
Further development of the quaternary amine platinum compounds, previously 
discussed in Chapter 4 also may prove atttractive. Derivatives particularly of the Brij® 
type of non-ionic detergent solubilizers (PEGylated C12-C18 fatty alcohols), are attractive, 
with lipophilicity, aqueous solubility, and lower toxicity than ionic detergents. The 
quaternary amine platinum compounds, with a straightforward synthesis, even 
combinatorial for the initial model studies, could rapidly lead to the isolation of soluble 
lipophilic platinates with good activity, a goal that has so far proved unattainable. 
In summary, this research has helped to lay a foundation of synthetic routes to 
additional MGd conjugates and potential Pt therapeutic agents. We had hoped to progress 
both further and faster in this work. Ultimately, we take satisfaction in having helped 
smooth the path for those who are to follow. 
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Appendix: Synthesis of Additional MGd-Pt Conjugate 
The activity of MGd-Pt conjugate 3.1 inspired the synthesis of MGd-Pt 
conjugates A1 (Scheme A1). Due to the difficult purification of this final product due to 
low water solubility, discussion has been moved to this appendix.   
For A1, the second conjugate, the previously reported halo-veratrole 3.9 was 
synthesized from guiaicol (Scheme A1).256  Condensation with methyl diethylmalonate in 
the presence of NaH gave diester 3.10. Hydrolysis under basic conditions was essentially 
quantitative. This gave the diacid 3.11 with no evidence of decarboxylation, a process 
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Scheme A1  Synthesis of MGd-Pt conjugate A1. 
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that is generally attributed to a thermal reaction.257 Although decarboxylation during 
nitration was a concern, nitration of guiaicol acetate had been previously reported.258  
Nitration at 0-25 oC gave the dinitrobenzene-malonate 3.12 in 54% yield. The 
dinitrobenzene-malonate intermediate 3.12, as in the synthesis of 3.1, was reduced, 
cyclized and metallated, to the desired MGd malonates A1. The lower solubility of this 
non-PEGylated model compound proved to be an issue. The crude material 3.13a (c.a. 
70% HPLC assay, LRMS identification) was platinated, as with the prior MGd-malonate 
conjugate, by exchange of acetate for nitrate anion, followed by metallation to give the 
MGd-Pt conjugate A1. Purification was effected as the nitrate salt on C-18 with 10-100 
mM KNO3 in methanol.  The material was characterized by MS, HPLC, HRMS and 
evaluated for stability.  
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Figure A1 Hydrolysis Study of MGd-Pt conjugates 3.1 and 3.2 in methanol and phosphaete 
buffered saline (PBS). Methanol (3.1 □, 3.2 ○), PBS (3.1 ■, 3.2 ●).   
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Purification of the MGd-malonate acetate salt 3.13a could not be effected as the 
nitrate salt on C-18 due to low solubility. The acetate salt could be purified on C-18 using 
MeOH and acetonitrile containing HOAc (1-2%), at high organic concentrations. This 
procedure gave a product which by HRMS analysis agreed with a product containing one 
esterified alcohol and a single acetate. It remained non-obvious which acid was esterified.   
In HPLC stability studies, Figure A1,  the hydrolytic profile of conjugate 3.1 
demonstrated t1/2 = 3 days (the above, additional, tertiary malonate model conjugate 
containing a PEG2 linker, A1 and a propyl linker conjugate were also prepared and both 
demonstrated an aqueous hydrolysis profile with t1/2 = 9 days, the PEG conjugate Pt loss 
was confirmed as reversible on the addition of Pt-diaquo) The hydrolysis, as with the 
previous HPLC hydrolysis study, was reversible and the peak attributed to conjugate A1 
could be regenerated by the addition of “diaquo-Pt.” Stirring the hydrolysis solution of 
A1 (obtained on day 9) for one day at room temperature with excess “diaquo-Pt” resulted 
in the peak area at the retentiono time for conjugate A1 incereasing from 45% to 76%, 
with a corresponding decrease in the peak seen to increase during the hydrolysis study.  
While this latter guiaicol-type analogue demonstrated lower water solubility than 
MGd-Pt conjugate, this work has developed a flexible synthetic route to a scaffold for 
conjugation of MGd with Pt chemotherapeutic agents. The convergent synthetic scheme 
allows for variation of both malonate substitution to modify release rates and phenyl ring 
substitution to modify lipophilicity via solubilizing PEG spacers. This flexibility may 
allow combinatorial synthesis for tuning the Pt release rates as well as solubility and 
lipophilicity of the conjugates. 
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EXPERIMENTAL 
 
Synthesis of 1-[2-(2-Chloro-ethoxy)-ethoxy]-2-methoxy-benzene 3.9.259 To a 
solution of guiaicol (12.7 g, 102 mMol) and 1-Chloro-2-(2-chloro-ethoxy)-ethane (24 g, 
128 mMol) was added NaOH (40 ml, 2.5 N). The solution was held at 70 oC for 24 hours. 
On cooling the solution was added to ice water (500 ml) and extracted with 
EtOAc:hexanes (2:1, 225 ml), washed with water, dried over MgSO4, and evaporated to 
give an oil. The oil was extracted with hexanes (2 x 200 ml) to extract the product. The 
pooled hexanes were filtered through a bed of silica gel (50 ml) and the bed washed with 
hexanes (100 ml) and EtOAc (150 ml). The hexane fraction was discarded, and the 
EtOAc layer was evaporated to give the product as an oil (12g, 51%). HPLC (270nm): Tr 
13.14 min; 53.33%. MS (CI) (M+H)+ = 231. 1H NMR(400 MHz, CDCl3) δ 6.83 (4), 
4.18 (2H, t), 3.90 (2H, t) 3.83 (2H, t) 3.77 (2H, t). The crude product could be purified 
with difficulty by RP C-18 chromatography. This material contains residual bis-
substituted product and the dihhalide. In preparative scale reactions the material was 
alkylated with excess methylmalonate. In preparative scale work purification is most 
easily effected at the dicarboxylic acid stage. 
Synthesis of 2-{2-[2-(2-Methoxy-phenoxy)-ethoxy]-ethyl}-2-methyl-malonic 
acid diethyl ester. 3.10  To a suspension of NaH (60% in oil, 16.5 g, 410 mMol) in DMF 
(400 ml) was added methyldiethylmalonate (70 ml, 400 mMol). After the hydrogen 
evolution was complete 1-[2-(2-Chloro-ethoxy)-ethoxy]-2-methoxy-benzene (100 g, 450 
mMol) was added. The solution was   held at 110 oC for 24 h. On cooling the solution 
was added to water (1000 ml) and extracted with hexanes:EtOAc (2 x 200 ml) followed 
by washing with water (3 x 100 ml) and drying over MgSO4.  Purification by flash 
chromatography over silica gel (hexanes/EtOAc) provided the product as an oil (100 g, 
91 
79%). The crude material was of adequate purity  for use in the next reaction. HPLC  
(269nm):Tr 14.68 min, 93.68%. 1H NMR(400 MHz, CDCl3) δ 1.21 (6H, t J = 7.2 Hz), 
1.42 (3H, s), 2.19 (2H, t J = 7.8 Hz), 3.59 (2H, t J = 6.8 Hz), 3.75 (2H, t, J = 5.1 Hz), 3.83 
(3H, s), 4.13 (6H, m), 6.89 (4H, m). 13C NMR(100 MHz, CDCl3) δ 13.8, 19.8, 34.9, 51.9, 
55.7, 61.1, 67.2, 68.3, 69.1, 111.8, 113.9, 120.7, 121.3, 148.1, 149.5, 172.0. MS(EI) 
(M+H)+ = 369. HRMS(EI) calculated for C19H28O7 369.1913, found 369.1917. Anal. 
Calcd for C19H28O7: C 61.94%; H 7.66%. Found C 61.26%; H 7.89%. 
Synthesis of 2-{2-[2-(2-Methoxy-phenoxy)-ethoxy]-ethyl}-2-methyl-malonic acid. 
3.11 To a solution of the diester (53 g, 147 mMol) in EtOH (250 ml) was added NaOH 
(200 ml, 2.5 N, 500 mMol). The solution was   stirred overnight. The reaction was complete 
by tlc and the solution was added to water (400 ml) and washed with hexanes:EtOAc (200 ml 
3:1). The aqueous layer was then acidified with HCl (3 N) and the aqueous layer extracted 
with EtOAc:DCM (2 x 200 ml, 3:1) which was back extracted with NaOH (2.5 N, 150 ml). 
The resulting aqeous solutin was acidified to pH = 2 with HCl (3N) and extracted with DCM 
(100 ml), dried over MgSO4 and evaporated to give the product (15 g, 33% theo). HPLC 
(335nm): Tr 12.24 min, 91.11%. 1H NMR(400 MHz, CDCl3) δ 1.62 (3H, s), 2.30 (2H, t J 
= 5.1 Hz), 3.66 (2H, t J = 5.1 Hz), 3.75 (2H, m), 3.95 (3H, s), 4.06 (2H, m), 6.90-6.94 
(4H, m). 13C NMR(400 MHz, CDCl3) δ 21.2, 36.1, 50.9, 55.7, 66.9, 67.4, 68.7, 111.7, 
112.0, 120.9, 121.3, 147.9, 148.2, 176.6. MS (EI-) (M-H)  311 HRMS(EI) calculated for 
C15H19O7 [M-1] 311.1494, found 311.1136. Anal. Calcd for C15H19O7 .2H2O: C 51.87%; H 
6.62%. Found C 52.84%; H 6.85%. 
Synthesis of 2-{2-[2-(2-Methoxy-4,5-dinitro-phenoxy)-ethoxy]-ethyl}-2-
methyl-malonic acid 3.12  A solution of the diacid (3.35g, 11 mMol) in HOAc (6 ml) 
was  cooled to 10 oC and conc. HNO3 (6 ml) was added solwly over 30 minutes. The 
solution was stirred for 2 hours, recooled to 8 oC and fuming HNO3 (8 ml) was slowly 
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added. After 0.5 h at less than 10 oC additional fuming HNO3 (4 ml) was added. After 
stirring overnight and being allowed to slowly warm to room temperature the solution 
was added to 100 cc crushed ice and centrifuged to give an oil. The aqueous layer was 
decanted and the remaining oil was partitioned between brine (50 ml) and EtOAc (75 
ml).  The organic layer was washed with water (4 x 50 ml). Evaporation gave the product  
as a yellow oil (2.52 g, 54% ). HPLC (269nm): Tr 11.07 min, 88.20%. 1H NMR(400 
MHz, CDCl3) δ 1.56 (3H, s), 2.26 (2H, t J = 5.1 Hz), 3.68 (2H, t J = 5.1 Hz), 3.78 (2H, 
m), 4.05 (3H, s), 4.21 (2H, m), 7.30 (1H, s), 7.39 (1H, s). 13C NMR(100 MHz, CDCl3) δ 
20.6, 36.0, 57.5, 68.5, 69.6, 70.5, 108.3, 109.3, 137.1, 137.5, 152.3, 153.4, 175.7. MS 
(EI) (M)+ 402. HRMS(EI) calculated for C15H19N2O11 403.0989, found 403.0987. Anal. 
Calcd for C15H18N2O11: C 44.78%; H 4.51%; N 6.97%. Found C 39.21%; H 2.38%; N 
11.71%. 
 Synthesis of MGd-malonate. 3.13 To a solution of 3.12 (7.5 g, 18.6 mMol) in 
EtOH (200 ml 1:1) with 10% Pd/C (1.07 g.) was hydrogenated overnight at 40 psi.  The 
resulting solution was filtered and added to a solution of  3.6 (9.21 g, 19.1 mMol) and 
HOAc (1 ml) in MeOH(600 ml).  After heating at 50 oC for 8 h the red solution was 
evaporated. The resuidue was added to a solution of Gd(OAc)3 (10.29 g,  25.7 mMol) and 
Et3N (20 ml) in MeOH (600 ml) saturated with air in the dark at 50 oC for 8 h gave a 
deep green solution.  The reaction was quenched by adding HOAc (30 ml) and the 
solution was filtered though celite and evaporated. The residue was washed with hexanes, 
toluene and Et2O. The residue was then suspended in acetone and precipitate with the 
addition of hexanes. The product was dissolved in MeOH and precipitated with Et2O (5x 
volume) to give the crude green solid product (16.45 g, 79%). Further purification was 
effected by dissolving the crude solid (1.15 g) in MeOH (10 ml), diluting with DCM (80 
ml) and loading onto silica gel (50 cc). The silica gel was washed with 
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DCM/MeOH/HOAc solutions; 85/15/0, 85/15/1, 60/40/1. The first two washes reoved 
the soluble red by products, the third solution eluting the product from the silica gel. 
Evaporation of the product solution and tituration with Et2O gave the green product (0.75 
g, 65%). The solid was then dissolved in MeOH (1g/10 ml), diluting with an equal 
volume of NH4OAc (100 mM) buffer, and loading on a tC-18 SPE cartridge (10 g). 
Elution with NH4OAc (100 mM) buffer:acetonitrile solutions, 50:12 and 50:20 gave 
solutions containing impurities and the product respectively. The product fraction, after 
dilution with an equal volume of buffer was again loaded onto a fresh tC-18 column, 
washed with water, and the product eluted with acetonitrile:HOAc 95:5. The resulting 
solution was evaporated under high vacuum, dissolved in a minimal amount of MeOH 
and precipitated with Et2O to give a green solid (0.23g, 20% yield overall). HPLC (470 
nm): Tr  10.59 min, 96.20%. MS (EI+) (M-OAc)+ 999, 983 (EI-) 982. HRMS(EI+) 
calculated for C45H55N5O10Gd 983.3185, found 983.3178. HRMS(EI-) calculated for 
C45H55N5O10Gd 981.3039, found 981.3055. The predominant product by HRMS gave 
results in agreement with (M-OAc ester  + H2). A minor product also observed was in 
agreement by HRMS (EI-) with (M-OAc ester + H2 +O2): calculated for C45H55N5O12Gd 
1015.3080, found 1015.3087. Anal. Calcd for C47H58GdN5O13: C 53.34%; H 5.52%; N 
6.62%. Found C 58.98%; H 5.68%; N 8.30. 
Synthesis of MGd-Pt conjugate. 3.2 To a solution of 3.13 (260 mg, 0.23 mMol) 
in MeOH (10 ml) was added a solution of (NH3)2Pt(H2O)2+2(NO3)2-  (5 ml, 0.23 mMol) and 
stirring overnight gave the crude product. Purification was effected by adding the solution (1 
ml) to KNO3 (5 ml, 100 mM) and loading on a tC-18 SPE cartridge (500 mg).  Elution with 
KNO3 (100 mM):acetonitrile solutions, 100:24 and 100:40 gave solutions containing 
impurities and the product respectively. The product fraction, after dilution with an equal 
volume of buffer was was loaded onto a fresh tC-18 column, washed with water and the 
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product eluted with MeOH/ KNO3 (10 mM, 95:5). The product solution was titurated with 
Et2O to give a green solid (26 mg, 8%). HPLC (470 nm): Tr  9.92 min, 96.72%.  
HRMS(EI) calculated for C43H56N8O12PtGd 1228.294, found 1228.290. HRMS(EI) 
calculated for C43H57N8O12PtGd (M-NO3)+ 1229.293; found: 1229.292.  
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